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Abstract 
Identification of System Independent and Dependent Parameters for Reliable in vitro-in 
vivo Extrapolation of P-glycoprotein using a Mass Action Kinetic Model 
Zhou Meng 
Joe Bentz, Harma Ellens, supervisors, Ph.D. 
 
The purpose of this work is to investigate the best kinetic parameters for incorporation 
into mechanistic PBPK model for P-gp using a mass action kinetic model. We first 
showed that by extending the P-gp kinetics analysis from confluent MDCKII-hDMR1 
cells monolayers to Caoc-2 cells monolayers, the elementary rate constants governing P-
gp’s binding and efflux (on-, off- and efflux rate constants: k1, kr and k2) remain constant 
between two cell lines, therefore independent of the in vitro system in which they are 
generated. In addition, we kinetically identified the involvement of a basolateral uptake 
transporters for digoxin and loperamide in Caco-2 cells, which were also seen in 
MDCKII-hMDR1 cells. This again demonstrates the value of our P-gp structural model 
as a diagnostic tool in detecting the presence of other transporters, which cannot be done 
unambiguously by Michaelis-Menten approach. Our results suggest the hypothesis that 
the elementary rate constants of P-gp obtained from in vitro would be reliable for 
incorporation into mechanistic PBPK models for transporters. We also investigated the 
P-gp expression-activity relationship and showed that in Caco-2 cells total P-gp is much 
greater than efflux active P-gp, while in MDCKII-hMDR1 cells the values are fairly 
similar. In addition, we found that the microvilli in Caco-2 cells are taller and more 
densely packed than those in MDCK-hMDR1 cells, which would lead to a substantial 
fraction of P-gp in Caco-2 cells not contributing to final release of drug into the apical 
chamber, but instead being involved in a futile cycle of drug efflux followed by 
 xii
reabsorption. The effect of microvilli morphology differences between in vitro and in 
vivo systems should be considered when scaling transporter activity for P-gp and 
possibly other efflux transporters.  In summary, all our findings as shown in this thesis 
will allow for a future robust PBPK model building.   
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Chapter 1: Introduction 
1.1 Membrane transporters 
1.1.1 Physiological and pharmacological role                                             
Membrane transporters mediate the movement of endogenous ions, small molecules, or 
macromolecules, such as protein, across a biological membrane. They are generally 
divided into two major superfamilies: (1) the ATP binding cassette (ABC) family which 
utilizes the energy from ATP hydrolysis to transport substrates across the membrane; (2) 
the solute carrier (SLC) family which can be either facilitative transporters moving their 
substrate down the concentration gradient across the membrane, or secondary active 
transporters moving their substrate against the gradient using an external source of 
energy. To date, more than 400 membrane transporters in these two superfamilies have 
been annotated in the human genome(Giacomini et al., 2010). 
Besides physiological compounds, many membrane transporters also recognize a variety 
of structurally diverse xenobiotics including environmental compounds, dietary 
compounds, drugs and drug metabolites. Transporters are widely expressed in the 
intestine, liver, kidney, and brain involving the uptake and efflux of drug. Numerous 
studies have suggested that membrane transporters play an important role in drug 
absorption, distribution and elimination, which altogether determine the drug safety and 
efficacy(Giacomini et al., 2010).           
 
1.1.2 ABC transporters  
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One of the largest classes of transporters is the ATP-binding cassette (ABC) transporter 
superfamily (Holland, 2003). ABC transporters function as either exporters, which efflux 
toxins, drugs out of cells, or as importers, which bring nutrients and other molecules into 
cells.  While there are both ABC importers and exporters in bacteria, most eukaryotes 
only have exporters(Vasiliou, Vasiliou, & Nebert, 2009; Wilkens, 2015). All ABC 
proteins have at least four core structures: two transmembrane domains (TMDs) and two 
ATP binding domains (or nucleotide binding domains (NBDs)). NBDs are located in the 
cytoplasm which bind and hydrolyze ATP to drive the translocation of bound ligand 
(Dean, Rzhetsky, & Allikmets, 2001). The hall mark of ABCs are the NBDs which 
contain three highly conserved motifs: the Walker A/P-loop 912 amino acids), a 
Signature motif/C-loop (5 amino acids) and the Walker B motif (5 amino acids). 
Prokaryotic ABC transporters are often comprised of separate protein subunits (two 
TMDs and two NBDs)(Biemans-Oldehinkel, Doeven, & Poolman, 2006). The two NBDs 
and TMDs can be different proteins (heterodimeric), or identical (homodimeric). 
Regarding eukaryotic exporters, they contain either of one polypeptide chain serving for 
all the domains or a dimer of two polypeptides with each containing an NBD and a TMD. 
In addition to the four main domains, importers of bacteria required an accessory subunit 
to capture their substrate and deliver them to the binding site in the TMDs (Davidson, 
Dassa, Orelle, & Chen, 2008).  
Generally, ABC transporters move substrate against a concentration gradient, which 
requires ATP hydrolysis as a driving force. The basic catalytic cycle of ABC transporters 
has been demonstrated to involve several steps: (1) direct binding of a substrate to the 
TMDs in exporters or binding of substrate binding proteins of a substrate in importers; (2) 
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binding of two MgATP molecules to the NBDs followed by NDBs dimerization; (3) 
conformation switching of the TMDs between the in- and outward facing; (4) ATP 
hydrolysis; and (5) release of product followed with NBD dissociation to reset to the 
original state (Wilkens, 2015).  
1.1.3 Role of ABC transporters in human disease and multidrug resistance 
Multidrug resistance (MDR) is the principle mechanism by which many cancers develop 
resistance to chemotherapy drugs(Persidis, 1999). A common mechanism of MDR is the 
over expression of ABC transporters in cancer cells, such as P-glycoprotein (P-
GP/ABCB1), multidrug resistance-associated protein (MRP1/ABCC1) and breast cancer 
resistance protein (BCRP/ABCG2) (Borst & Elferink, 2002). It has become clear that 
these transporters play a critical role in limiting the drug absorption from the intestine as 
well as drug distribution into tissue, such as in brain and testis.   
There is an increased number of inherited human diseases found to be caused by defects 
in ABC transporter genes. 24 of 48 ABC genes which were defined in the human 
genome have been linked to human diseases (Borst & Elferink, 2002).  The most 
common genetic disease conditions include (but are not limited to) cystic fibrosis, 
Alzheimer’s disease, Tangier disease, age-related macular degeneration, Dubin-Johnson 
syndrome and progressive familial intrahepatic cholestasis (Borst & Elferink, 2002; 
Gottesman & Ambudkar, 2001; Tarling, de Aguiar Vallim, & Edwards, 2013).  
1.2 P-glycoprotein/MDR1 
1.2.1 Discovery and role in multidrug resistance 
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The multidrug resistance (MDR) phenotype is characterized by cross-resistance to 
unrelated drugs and increased efflux from cells resulting in lower drug accumulation in 
cells. (Gottesman & Ling, 2006). Using MDR cell lines (Ehrlich ascites humor cells), 
Dano et al. demonstrated that there is an energy dependent efflux of the cytotoxic 
compound daunomycin and inhibition of this putattive efflux pump led to the increase in 
drug accumulation (Dano, 1973). Later, Ling and Thompson isolated clonal Chinese 
hamster ovary cells with colchicine resistance (CHR) and showed its cross resistance to 
other drugs (Ling & Thompson, 1974). P-glycoprotein expression was first demonstrated 
by the same group of people in these colchicine resistant cells, which was found absent in 
the parent cells (Juliano & Ling, 1976). P-gp was found to localize in the plasma 
membrane of CHR cells in significant amounts (estimated to be 3-4% of total plasma 
membrane protein) and the amount of P-gp correlated with the level of colchicine 
resistance. In 1986, MDR1 gene was identified to encode P-gp (Ueda et al., 1986). By 
1988, it was clear that P-gp is not only expressed in MDR cell lines, but also in normal 
tissue, such as adrenal cortex, renal tubules and placenta (Sugawara et al., 1988). In 1994, 
Schinkel et al. observed that MDR1 knock out mouse has blood-brain barrier defects and 
first showed that P-gp plays a role in drug pharmacokinectis(Schinkel et al., 1994). 
Ultimately, P-gp was defined as a primary efflux pump that uses the energy from ATP 
hydrolysis to actively extrude its substrate from cells. In 2009, the first mouse P-gp X-
ray crystal structure was revealed for better characterization of substrate-binding and 
solute translocation mechanism of this key drug transporter(Aller et al., 2009). Later, C. 
elegans P-gp X-ray crystal structure with higher resolution (Jin, Oldham, Zhang, & Chen, 
2012) and a refined mouse P-gp crystal structure were also revealed(J. Li, Jaimes, & 
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Aller, 2014). Today, P-gp remains the best studies and characterized membrane 
transporter.  
1.2.2 Structure and mechanism of action 
P-gp is a 170 kDa molecule comprised of two pseudosymmetric halves with each 
containing a nucleotide-binding domain (NBD) and a transmembrane domain (TMD). It 
is believed that P-gp functions via an alternate access mechanism involving two different 
conformations, known as “alternating access” model.(Ward et al., 2013) (Hollenstein, 
Dawson, & Locher, 2007; Jardetzky, 1966; Senior, al-Shawi, & Urbatsch, 1995; van 
Wonderen et al., 2014). According to this model, binding of ATP at the NBDs stimulates 
the conformational changes in the TMDs from inward-facing (inverted V appearance) to 
outward-facing. This ATP-driven switch results in the delivery of substrates out of the 
cell. Hydrolysis of ATP is believed to reset the protein to the inward-facing form to wait 
for a new cycle of drug binding and release. This model is supported by the P-gp X-ray 
structures without nucleotide binding observed in mouse (J. Li et al., 2014) and 
Caenorhabditis elegans (Jin et al., 2012), as well as the X-ray structure  of SAV1866 (a 
bacterial ABC transporter) (R. J. Dawson & Locher, 2006).  
1.2.2.1 P-gp portals  
Raviv et al. and Shapiro et al. first revealed that the substrate binding site of P-gp was in 
the inner leaflet of plasma membrane instead of the aqueous cytosolic medium(Raviv, 
Pollard, Bruggemann, Pastan, & Gottesman, 1990; Shapiro & Ling, 1998). From recent 
X-ray structures of mouse P-gp, two portals were identified open to the inner leaflet of 
the membrane, delineated by the α-helices TMs 3 and 4 on one side and TMs 9 and 10 on 
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the other side (J. Li et al., 2014; Ward et al., 2013). The crossovers of TM4 and 5 (and 
TM10 and 11) produce the portals and make extensive contacts with the α-helices bundle 
of the opposite domain. These structures suggest the possibility of substrates entering the 
central binding sites through these particular portals or gates. In addition, this structural 
motif is also conserved in C. elegans P-gp with only difference that a N-terminal helical 
hairpin seems to block one of the portals (Jin et al., 2012). Recently, a refined structure 
of mouse P-gp was published(J. Li et al., 2014). The most notable change about the P-gp 
portals there was correction of position of TM4 and TM5. TM4 hadbackbone atoms 
shifted > 6 Å from their original positions while TM5 had a 90 degree rotation. In 
addition, the drug translocation pathway was found to be enriched in aromatic resaidues 
that likely play a collective role in allowing a high degree of polyspecific substrate 
recognition.  
1.2.2.2 P-gp binding sites 
For the transporters, the drug binding site is defined as the specific residues that trigger 
important protein conformational changes, leading to transport of substrate. In the later 
1990s, based on kinetic studies of drug transported in isolated P-gp-rich plasma 
membrane vesicles from CHO CHR B30 cells, Shapiro and Ling first proposed the 
existence of two distinct drug binding sites of P-gp, designated as H-site and the R-site 
due to the distinct drug specificities registered for Hoechst and rhodamine dye, 
respectively (Shapiro, Fox, Lam, & Ling, 1999; Shapiro & Ling, 1997). These two sites 
were found to be positively cooperating with each other. Later, a third drug-binding site 
was proposed, with a positive allosteric effect on both H- and R- sites due to possibly 
interfering with ATP-hydrolysis rate(Shapiro et al., 1999).  
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The breakthrough of clarification on the P-gp binding sites was the publication in 2009 
of the mouse crystallographic structure with a higher resolution (3.8 Å)(Aller et al., 2009). 
In this study, a large internal chamber of approximately 6000 Å was identified as the 
drug-binding pocket which opens to the intracellular compartment and the lipid 
membrane via two portals formed by pairs TMD 4/5 and 10/11. Three distinct drug-
binding sites which were located in the outer leaflet of the lipid bilayer, were proposed 
according to the residues chemical characteristics and docked structures of the cyclic 
peptide stereoisomers QZ59-RRR and QZ59-SSS. It is worth noting that these sites 
locate at the opposite side of H and R sites which occur next to the inner leaflet. In the 
recent refined mouse P-gp structure, with the improvement of drug-free structure, mouse 
P-gp crystals in the presenc of QZ59-RRR and QZ59-SSS were also refined(J. Li et al., 
2014). In addition, the registry of six transmembrane helices was corrected which 
revealed the amino acid residues involved in drug binding that were previously 
unrecognized. 
Although a great improvement has been achieved in terms of structure of P-gp binding 
sites, lots of work are still required for the thorough characterization of substrates binding 
sites which would allow the development of more potent and selective P-gp efflux 
modulators. 
1.2.3 Tissue distribution and function 
P-gp is expressed at high levels in the epithelial or endothelial cells with excretory and 
protective functions, such as the ones lining the small intestine, bile ductules and kidney 
proximal tubules (Brinkmann & Eichelbaum, 2001). P-gp expressed in the luminal side 
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of intestinal epithelia and bile-facing canaliculi of the liver plays an important role in 
first-pass of orally administered drugs by effluxing them into intestinal lumen and bile, 
respectively. P-gp is also involved in drug elimination by effluxing the substrates from 
the systemic circulation at the urine-facing side of the brush border membrane of 
proximal tubules in the kidney as well as through biliary excretion. In addition, P-gp is 
important in drug tissue distribution by restricting their permeability from apical side of 
blood-tissue barriers, such as blood-brain, blood-placenta, and blood-testis barriers 
(Fromm, 2004). Besides surface membrane localization in the cells, P-gp also was found 
intracellularly in several human tumor cell lines, such as in the endoplasmic reticulum , 
Golgi apparatus and the nuclear envelope, and considered to be associated with cell 
trafficking machinery (Arancia, Molinari, Calcabrini, Meschini, & Cianfriglia, 2001). 
However, P-gp was found to be almost exclusively expressed in the apical surface of 
MDCK-MDR1 and Caco-2 cell lines, the ones we used in the experiment (Anderle et al., 
1998; Hutter et al., 2014).    
1.2.4 P-gp related drug-drug interaction  
As discussed above, P-gp plays a vital role in the drug absorption, distribution and 
elimination. Therefore, the change of expression level and functionality of P-gp through 
inhibition and induction can affect the drug pharmacokinetics, efficacy, safety or tissue 
levels. Numerous studies have characterized the interactions among P-gp compounds as 
co-administration can substantially alter the pharmacokinetic of the compounds involved 
and result in unwanted side effects (Aszalos, 2007). This is especially important for the 
drugs with narrow therapeutic window and little metabolism.  A number of drug 
interactions of clinical relevance are cited as warning in the drug labels by the Federal 
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Drug Administration (FDA). For example, the drug label for digoxin which is indicated 
for the treatment of heart failure and atrial fibrillation, warns against potential drug 
toxicity when administered with P-gp inhibitors, such as quinidine. Quinidine inhibition 
of P-gp results in an increase in digoxin absorption and a reduction of digoxin 
elimination, primarily via kidney, which substantially increases digoxin plasma 
concentrations (Wessler, Grip, Mendell, & Giugliano, 2013).   
Interaction of ABCB1 gene which encodes P-gp with other genes have been shown to 
play an important role in the P-gp substrate disposition. Most of time, genes responsible 
for the disposition of a drug can act synergistically (Liu & Hunt, 2006). For example, 
CYP3A4 is one of the most important drug-metabolizing enzymes. CYP3A4 and P-gp 
have an extensive overlap in their substrates spectrum. Examples of clinically relevant 
drug interactions due to the interplay of ABCB1 with CYP3A4 gene in the disposition of 
P-gp substrates are cyclosporine A (CsA) by CYP3A4 inhibition and rifampin by 
CYP3A4 induction (Marchetti, Mazzanti, Beijnen, & Schellens, 2007).  
1.3 2 Assays to study the kinetics of drug efflux via P-gp 
1.3.1 Vesicular assay system  
Protein reconstituted in lipids and membrane vesicle preparation can be used to study the 
functional properties of the protein(Banerjee & Datta, 1983; Yan, 2003). Based on the 
orientation of P-gp, the vesicle can either be right side out (ROV) or inside out (IOV).  
Regarding IVOs, compound can access the binding site of P-gp easily on the inner leaflet 
of membrane in the buffer when P-gp is facing inside of the vesicle. This system is 
thought to follow principles of enzyme kinetics because the transporter interact directly 
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with the substrate/inhibitor in the incubation medium and has been used in determining if 
a certain molecule is a substrate for P-gp. Vesicles are most suitable for low-permeability 
substrates because of poor retention of moderate- to high-permeability compounds. 
Given the fact that majority of P-gp substrate are lipophilic which exhibit greater 
permeability, the utility of vesicles may be limited. Therefore, efflux by P-gp is often 
studied in confluent cell monolayers (see discussion below). Another disadvantage of 
IOVs system is the significant non-specific binding and membrane leakage which leads 
to inaccurate measurement of transport(Sarkadi, Price, Boucher, Germann, & 
Scarborough, 1992). 
1.3.2 Polarized epithelial cell monolayer assay system  
The cultured polarized epithelial cell monolayer, where P-gp is expressed exclusively in 
the apical plasma membrane, is the most common in vitro cellular model. This system is 
often chosen because it is physiologically relevant and requires no biochemistry 
manipulations to measure transport(Tran et al., 2005). In this system, cells are grown on 
polycarbonate inserts until the apical-basolateral polarity is established. The transport of 
substrate across the monolayer is measured in both directions: apical to basolateral 
(absorption) and basolateral to apical (secretion).  
There are several major confluent cell lines that are commonly used for P-gp mediated 
transport, including: human colonic carcinoma cells (Caco-2), Madin-Darby Canine 
Kidney cells with overexpression of human MDR1 (MDCK-MDR1), Porcine Kidney 
cell line (LLC-PK1), and HCT8 cells. Each of these cell types has certain strengths and 
weakness. Here, Caco-2 cells and MDCK cells are reviewed.  
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One of the widely used cell lines for study of the role of P-gp in drug transport is Caco-2, 
which originates from a human colonic adenocarcinoma. Caco-2 cells tend to 
differentiate based on selective environmental pressures, resulting in possible change in 
protein concentration on the surface of membranes (Anderle et al., 1998). One of the 
changes is the increased expression of P-gp in its apical membrane as well as exhibition 
of morphological and functional similarities to intestinal (absorptive) enterocyte. Another 
reason why Caco-2 cells are popular is that they are of human origin, compared to 
MDCK and LLC-PK1. The cells form tight junctions and express many brush border 
enzymes as well as some CYP450 isoenzymes, which makes them a nice model to study 
the interaction between P-gp and enzyme metabolism.  
However, use of Caco-2 cell monolayers has certain disadvantages. First, cell lines may 
have different characteristics and transporter expression level depending on the interval 
of passage number at which the cells are studies. Therefore, it is important to limit the 
number of passages that are used for the experiment. For example, Caco-2 cells obtained 
from American Type Culture Collection (ATCC) are suggested to use between passage 
numbers 20-40 while Caco-2 cells from other sources are usually used at much higher 
passage, e.g. 90-105. Caco-2 cells also are sensitive to different growth conditions, which 
may underlie the substantial lab-to-lab variation. Second, culture of Caco-2 cells is labor-
intensive and time consuming, since it takes 21-28 days to become confluent, and 17-27 
days for P-gp to become fully functional(Hosoya, Kim, & Lee, 1996; Tang & Borchardt, 
2002). As alternatives, protocols that shorten the differentiation process down to 1 week 
were published(Liang, Chessic, & Yazdanian, 2000; Tang & Borchardt, 2002). However, 
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the information regarding the performance of these protocols, e.g., stability of P-gp 
expression, is lacking.  
MDCK cells are a dog kidney epithelial cell line that has been widely used as an 
alternative to Caco-2 cells (Irvine et al., 1999). MDCK cells share many epithelial cell 
characteristics with Caco-2 cells, and their permeability values for many drugs also 
demonstrate a good correlation with human absorption data (Irvine et al., 1999). They 
were also proposed to be a valuable tool for rapid permeability screening of discovery 
compounds (Irvine et al., 1999). These cells can be transfected with human MDR1 gene 
where P-gp expression is higher and more stable compared to Caco-2 cells, which leads 
to the more reproducible flux data. MDCK cells also form tight junctions much more 
rapidly than Caco-2 cells (4 vs 21 days). However, the expression of canine P-gp, which 
has 80% structural similarity to human P-gp), may potentially complicate interpretation 
of data. We were aware of this situation when using MDCK-MDR1 cells to study the P-
gp kinetics. According to our results, the substrates transport level did not seem to be 
affected by species of P-gp as the elementary rate constants we obtained from MDCK-
MDR1 cells which express both human and canine P-gp and Cac-2 cells which expresses 
human P-gp only, were the same.  
Despite the fact that the polarized epithelial cell monolayer is a more physiologically 
relevant system in study of P-gp’s function, one serious drawback is the presence of 
multiple transporters in this system, which could be both endogenous and/or transfection 
induced (Acharya et al., 2008; Flanagan et al., 2002; Goh et al., 2002; Lowes, Cavet, & 
Simmons, 2003; Q. Wang et al., 2008). Transport of P-gp substrates across the cell 
monolayer could be contributed by other transporters in addition to P-gp alone. In other 
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words, kinetic parameters obtained in this way may not be P-gp specific. Therefore, 
although polarized cell monolayer is a good system to study P-gp function, data obtained 
must be carefully analyzed to avoid biased result.   
1.4 Estimation of P-gp efflux transport kinetics in confluent cell monolayer 
Initially, one of the most commonly used in vitro experimental approaches to assess the 
P-gp mediated efflux activity across confluent cell monolayer was to determine 
transcellular flux at various initial donor concentrations, which could give the maximal 
achievable transport rate (Jmax) and the donor chamber concentration associated with 
half-maximal transport rate (EC50). The Michaelis-Menten approximations to enzyme 
kinetics was directly applied to monolayer flux data and equaled the Jmax and EC50 to the 
efflux transport Vmax and Km, respectively (Troutman & Thakker, 2003). However, 
monolayer flux does not follow the principles of simple enzyme kinetics as there are 
additional barriers, such as basolateral and apical membranes, in the system. So the 
maximal achievable transport rate does not reflect active efflux activity (Kalvass & 
Pollack, 2007). This misinterpretation of Jmax and EC50 led to the wrong perception that 
efflux transport parameters cannot be consistently estimated. One of the examples is that 
P-gp Km estimates varied up to 27-fold when estimated using Michaelis-Menten kinetics 
directly to flux data in five different monolayers (Shirasaka, Sakane, & Yamashita, 2008).  
Later, compartmental models and a structural model have been developed to determine 
the kinetic parameters for P-gp in cell monolayers and each provides different levels of 
mechanistic detail. Compartmental models generate Michaelis-Menten parameters Km 
and Vmax based on steady-state Michaelis-Menten approach and initial rate. In contrast, 
the structural model uses the generally accepted mass action reactions, along with the 
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known structural parameters for P-gp (large substrate binding site accessible from the 
membrane), to generate elementary rate constants governing P-gp’s binding and efflux.  
1.4.1 Three-compartmental and five-compartmental models 
A three-compartmental model in polarized cell monolayer for efflux transport includes 
apical, basolateral, and cellular compartment (Kalvass & Pollack, 2007). In this model, 
passive diffusion through a cell is represented by a single clearance term CLd, and apical 
efflux is represented by CLae. The equations defining this model are complex and can be 
used to solve for CLd and CLae from single-point permeability data. With the 
assumptions that there is little lag time in flux and passive permeability across the apical 
and basolateral membrane are very similar, Michaelie-Menten parameters Km and Vmax 
can be calculated when there is no involvement of other transporters.However, the 
limitation of this model is that if these assumptions are invalid, such as appreciable flux 
lag time which is commonly observed in monolayer experiment, or other transporters 
involved in transport, then the mathematical relationship is no longer accurate(Anderson 
& Van Itallie, 2009; Korzekwa et al., 2012).  
Regading a five-compartment model, it has additional explicit membrane compartments 
(apical and membrane), although these compartments do not reflect apical and 
basolateral plasma membrane. Instead they reflect a pool of about half of the total 
cellular lipid on the apical side of the cell and the other half on the basolateral side. This 
model uses a membrane-to-water partition coefficient (Kp) to connect the substrate 
concentrations in the aqueous and membrane environment. Flux lag time occurs when 
the cellular concentration does not achieve rapid equilibrium after the substrates enter the 
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membrane and under this situation, the membrane compartments can serve as “storage” 
compartments (Korzekwa et al., 2012). Another advantage of this model is that it can 
describe substrate access to P-gp from membrane rather than from the cytosol. Therefore, 
this model can fit Km using free drug concentration in membrane.  
It has been shown that the Km fitted using intracellular concentrations predicted by a 
compartmental modeling approach were almost the same among various cells with 
different levels of P-gp expression (Tachibana et al., 2010). This cannot be achieved 
using the efflux ratio method, which models Km using extracellular substrate 
concentration(Shirasaka et al., 2008).  
1.4.2 Structural mass action kinetic model  
The structural model uses the generally accepted mass action reactions for P-gp binding 
and efflux, along with the known structural parameters for P-gp (large substrate binding 
site accessible from the membrane).  The model also considers the apical plasma 
membrane in which P-gp resides (the lipid bilayer partition coefficient of substrate and 
volume of apical plasma membrane allow estimation of substrate concentration at 
binding site). The model considers binding of substrates from within the inner leaflet of 
the apical membrane, with association rate constant k1, dissociation rate constant kr and 
efflux rate constant from P-gp into the apical chamber k2. The model also explicitly fit 
the P-gp efflux active surface density in the cells being used. For each new drug, these 
parameters were obtained by fitting multiple initial drug concentrations and multiple time 
points at each concentration for a long period (typically 6 hours), until final steady state 
is approached when P-gp mediated efflux into the apical chamber equals passive 
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permeability from apical chamber back into the cytosol. The rate constants obtained by 
this model have been shown to remain the same from one cell line to another (chapter 2). 
Moreover, this more detailed description of efflux from polarized confluent cell 
monolayers has been demonstrated to be a diagnostic tool in detecting the involvement of 
additional apical and basolateral uptake transporters in addition to P-gp mediated 
transport, which cannot be done by steady-state Michaelis-Menten approach (Acharya et 
al., 2008; Lumen et al., 2013). It also has provided insight into the unexpected 
relationship between P-gp IC50 and Ki in this system and possible explanation for the 
extreme lab-to lab variability in P-gp IC50 values observed for inhibition of digoxin 
transport (Bentz & Ellens, 2014).  
1.5 Translational modeling of transporter-mediated pharmacokinetics (PK) and 
drug interactions 
As the same case in drug-metabolizing enzyme, in vitro to in vivo extrapolation (IVIVE) 
of transporter mediated transport can apply either static or a dynamic physiologically 
based pharmacokinetics (PBPK) modeling approach. Basically, static model are based on 
clearance concepts and the drug concentration used to make the assessment is the Cmax 
rather than a concentration-time profile as in PBPK modeling. Regarding PBPK models, 
they integrate drug-dependent parameters obtained from in vitro, either a single clearance 
parameter or full kinetic characterization (Km and Vmax), with physiological and systems 
parameters to account for simultaneous absorption, distribution, metabolism, and 
excretion processes in predicting in vivo drug disposition (Rostami-Hodjegan, 2012). 
PBPK models have been applied to predict the impact of drug-drug interaction and 
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physiological conditions on drug pharmacokinetics, which may not be possible for static 
models. (Gertz et al., 2013; Zhao et al., 2011) 
Success in predicting transporter-mediated disposition in vivo depends on several aspects: 
(1) obtaining kinetic parameters that are system independent and reliable to be 
extrapolated from in vitro to in vivo. Whenever possible, full kinetic characterization of 
transporters of relevance, i.e., generation of Km and Vmax or elementary rate constants, is 
encouraged to be used for subsequent IVIVE, (2) bridging the functional and protein 
expression difference between in vitro and in vivo systems. One of the commonly used 
method is to incorporate the difference on the expression of drug transporters in in vitro 
and in vivo; (3) understanding the uncertainty associated with the parameters obtained 
from in vitro, e.g. Km obtained for low passive permeability drugs is not P-gp specific 
and may be the convolution with other transporters (Bentz & Ellens, 2014); (4) 
completeness of mechanistic consideration in the PBPK model structure; and (5) 
availability of clinical data for validation or refining model (top-down modeling 
techniques) (Barton et al., 2013; R. Li, Barton, & Varma, 2014).  
1.6 Conclusion  
P-gp plays an important role in drug disposition, distribution and elimination. It is also 
the driving mechanism of drug-drug interaction. The best parameters for incorporation 
into mechanistic PBPK models for P-gp are system independent kinetic parameters and 
active (not necessarily “total”) transporter levels. In the following chapters, I will 
demonstrate (1) the elementary rate constants governing P-gp’s binding and efflux 
obtained by structural mass action kinetic model remain constant when extrapolated from 
one cell line to another; (2) Microvilli morphology is an important factor in 
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determination of efflux active P-gp number. All these findings will allow for a robust 
PBPK building in future.  
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Abstract 
The best parameters for incorporation into mechanistic PBPK models for transporters are 
system independent kinetic parameters and active (not necessarily “total”) transporter 
levels. Previously, we have determined the elementary rate constants for P-gp mediated 
transport (on-, off- and efflux rate constants: k1, kr and k2) using the structural mass 
action kinetic model in confluent monolayer of MDCKII-hMDR1 cells. In the present 
work, we extended the kinetic analysis to Caco-2 cells and found that the elementary rate 
constants are very similar compared to MDCKII-hMDR1 cells.  Therefore independent 
of the in vitro system in which they are generated. Our results also showed that the 
estimated level of efflux active P-gp in Caco-2 cells was 4.4 fold lower than in MDCKII-
hMDR1 cells. In addition, we kinetically identified the involvement of a basolateral 
uptake transporters for digoxin and loperamide in Caco-2 cells, which were also seen in 
MDCKII-hMDR1 cells. This again demonstrates the value of our P-gp structural model 
as a diagnostic tool in detecting the presence of other transporters, which cannot be done 
unambiguously by Michaelis-Menten approach. Our results suggest the hypothesis that 
the elementary rate constants of P-gp obtained from in vitro would be reliable for 
incorporation into mechanistic PBPK models for transporters.  
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2.1 Introduction  
Numerous studies have shown that drug transporters play a significant role in drug 
absorption, distribution and elimination, and that their inhibition or induction can lead to 
sometimes serious drug-drug interactions (DDIs). The importance of transporters as 
driving mechanisms of DDIs has been reviewed recently (Giacomini et al., 2010; Zolk & 
Fromm, 2011) and transporter DDI risk assessment strategies for drug development have 
been outlined in Regulatory Guidance documents (US FDA/CDER, 
2012; 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm0
64982.htm, European Medicine Agency (EMA), 2013; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/
WC500129606.pdf). Physiologically Based Pharmacokinetic modeling (PBPK) is 
gaining increased acceptance by Regulatory Agencies as a tool to address DDI questions 
and in some cases can eliminate the need for a clinical DDI study (Huang, Abernethy, 
Wang, Zhao, & Zineh, 2013). 
P-glycoprotein (P-gp), a member of the ATP binding cassette (ABC) family of proteins, 
has been extensively studied due to its ability to efflux a broad range of drugs across 
biological membranes and important role in DDIs (Giacomini et al., 2010). The most 
common experimental system to obtain in vitro kinetic parameters for incorporation into 
PBPK models is a polarized cell monolayer overexpressing P-gp. The study of P-gp 
kinetics is complicated by the fact that the substrate binding site on P-gp is located within 
the inner monolayer of the apical membrane. Lumen et al., using a structural mass action 
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kinetic model (see below), demonstrated mathematically that the IC50 values for P-gp 
inhibition obtained using polarized P-gp expressing cell monolayers depended on P-gp 
expression level: higher P-gp levels result in higher IC50 values (Lumen et al., 2013). The 
physical basis for this is that higher P-gp expression results in lower intracellular 
concentrations of both substrate and inhibitor. The “true” Km and IC50 values need to take 
into account the intracellular concentrations of substrate and inhibitor.   
For study of P-gp efflux kinetics, the most commonly used mathematical models are 
compartmental models, which rely on initial rate data and steady state Michaelis-Menten 
assumptions to generate values for Km and Vmax (Zamek-Gliszczynski et al., 2013).  
Tachibana et al. recently used this modeling approach to demonstrate that Km values 
calculated based on extracellular concentrations depended on P-gp expression levels, 
whereas those based on intracellular concentrations did not (Tachibana et al., 2010). 
However, it is important to point out that a true Km value for binding to Pgp can only be 
derived in this way when the compounds have been demonstrated to interact with P-gp 
only and not with other transporters in the experimental in vitro system. Otherwise, Km 
and IC50 will be a convolution of binding to P-gp and another transporter(s) and therefore 
dependent on the in vitro experimental system and not reliable for use in a mechanistic 
PBPK model.          
We have developed a structural mass action kinetic model for P-gp mediated transport 
(Acharya et al., 2008; Agnani et al., 2011; Lumen et al., 2013; Tran et al., 2005). The 
structural model uses the generally accepted mass action reactions for P-gp binding and 
efflux (equation 1), along with the known structural parameters for P-gp (large substrate 
binding site accessible from the membrane).  The model also considers the apical plasma 
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membrane in which P-gp resides (the lipid bilayer partition coefficient of substrate and 
volume of apical plasma membrane allow estimation of substrate concentration at 
binding site). 
                                               
1 2
r
k k
0 PC 1 0 Ak
T C T T C→+ → +←                               (1) 
T0 is the empty transporter, CPC is the substrate in the apical membrane inner monolayer, 
T1 is the transporter bound by substrate and CA is the substrate after efflux into the apical 
chamber. The elementary rate constants are k1 for association with P-gp, kr for 
dissociation from P-gp back into the membrane and k2 for efflux out to the apical 
chamber. With this model, the elementary rate constants for several P-gp substrates as 
well as efflux active P-gp surface density, which make up the Km and Vmax, were 
successfully obtained in confluent MDCKII-hMDR1 cell monolayers.  Importantly, this 
model can detect kinetic involvement of additional uptake transporters for substrates with 
relatively low passive permeability, i.e., digoxin, vinblastine and loperamide (Lumen et 
al., 2013).The kinetic parameters are specific to P-gp even in the presence of other 
transporters. 
In this work we have investigated whether the elementary rate constants obtained by our 
mass action kinetic model can be extrapolated to other in vitro systems. We extended our 
kinetic analysis of P-gp mediated transport from MDCKII-hMDR1 cells to Caco-2 cells 
and demonstrated that the elementary rate constants, k1, k2 and kr, are very similar 
between MDCKII-hMDR1 and Caco-2 cell lines. This suggests that these parameters are 
system independent and can be reliably extrapolated from in vitro to in vivo, e.g. 
incorporated into a mechanistic PBPK model. In addition, our results provide kinetic 
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support for the presence of basolateral uptake transporters for digoxin and loperamide in 
Caco-2 cells, similar to MDCKII-hMDR1.   
2.2 Materials and Methods 
Loperamide, quinidine and digoxin were from Sigma (St. Louis, MO); amprenavir and 
GF120918 were from GlaxoSmithKline. 3H-amprenavir (24Ci/mmol) and 3H-loperamide 
(11 ci/mmol) were obtained from Amersham), 3H -digoxin (15-40 ci/mmol) was from 
Perkin Elmer, 3H –quinidine (20ci/mmol) was from American Radiolabeled Chemicals.  
SV 96 Total RNA Isolation System was from Promega.  Oligo (dT)12-18 primer, 
SuperScript® III Reverse Transcriptase, TaqMan® Universal PCR Master Mix  and 
Quant-iT™ RiboGreen® RNA Reagent were from Invitrogen (Carlsbad, CA,USA). 
Dimethyl sulfoxide and Lucifer yellow were from Sigma-Aldrich (St. Louis, MO). 
Dulbecco’s modified Eagle’s medium (DMEM) with 25 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid) (HEPES) buffer, high glucose (4.5 
g/L), L-glutamine, pyridoxine hydrochloride, without sodium pyruvate, and with phenol 
red was from Gibco (Grand island, NY). The same medium without phenol red was used 
for transport experiments. Fetal Bovine Serum, non-essential amino acids and penicillin-
streptomycin were from Gibco (Grand Island, NY). Transwell 12-well plates with 
polycarbonate insert (0.4 µM pore size and 12 mm in diameter) were obtained from 
Corning Life Sciences (Acton, MA). Epithelial Voltohmmeter (EVOM) and STX2 
electrode set were from World Precision Instruments (Sarasota, FL). 
2.2.1 Cell Culture 
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Caco-2 cells were maintained in culture media (DMEM supplemented with 10% Fetal 
Bovine Serum, 50 units/ml penicillin, 50 µg/ml streptomycin and 0.1mM MEM non-
essential amino acids). Cells were split once a week in a ratio of 1:20 at 70%-80% 
confluency after 2 washes with PBS and trypsinization with 0.25% 
trypsin/ethylenediaminetetraacetic acid (EDTA). Cells were kept at 37ºC in 5% CO2. All 
transport assays were performed with cells from passages 30-40.  
2.2.2 Quantitative Real-time RT-PCR (qRT-PCR) 
Total RNA from confluent MDCK-hMDR1 and Caco-2 cells monolayer was extracted 
using SV 96 Total RNA Isolation System according to the manufacturer’s instructions. 
cDNA was prepared by performing reverse transcription using an oligo (dT)12-18 primer 
and catalyzed by Superscript II enzyme according to the manufacturer’s instructions. 
Gene expression of MDR1 was then evaluated by qPCR. Thermocycling was carried out 
in a final volume of 25 μL containing 12.5 μL Taqman ® Universal PCR Master Mix, 
900 nM forward (5’-TATGGTGGTGGGAACTTTGGC-3’) and reverse (5’- 
CTGTCATTTCTCCAAACACCAGC-3’) primers, 250 nM probe (5’-(FAM)-
CCATGGGGCTGGACTTCCTCTCATGAT-(TAMRA)-3’) and 5 μL cDNA.  
Fluorescence was measured using the SDS software of the ABI PrismTM 7900HT 
Sequence Detection System (TaqManTM) starting with 10 minutes at 95 °C, followed by 
40 cycles of 15 seconds at 95 °C and 1 minute at 60 °C. Each sample was analyzed in 
triplicate. The targeted mRNA in MDCKII-hMDR1 and Caco-2 cells was normalized to 
total RNA. 
2.2.3 Caco-2 Cell Monolayer Culture and Transport Study 
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For the P-gp mediated transport experiment, cells were seeded on polycarbonate 
membrane inserts at a density of 2.5 × 105 / cm2 and maintained for 21 days in complete 
medium; the medium was changed every 2-3 days. After 21 days the monolayer integrity 
was determined by measuring the TEER using an Epithelial Voltohmmeter, according to 
manufacturer’s instructions.  The final values are expressed as Ω·cm2 on the basis of the 
following equation: TEER = (R-Ra ) × A, where R is the resistance of filter insert with 
cells, Ra is the resistance of the filter alone and A is the growth area of the filter. Mature 
Caco-2 cell monolayers exhibited a TEER > 600 Ω·cm2 before use in transport 
experiments. Prior to the experiment, media was removed and cells were pre-incubated 
for 30 minutes with either transport medium alone or transport medium supplemented 
with 2 µM GF120918 to inhibit P-gp. Transport of a range of concentrations of 
amprenavir, quinidine, loperamide and digoxin across the confluent monolayer of cells 
over 6 hours was measured in both directions, i.e. apical to basolateral (A>B) and 
basolateral to apical (B>A) in the presence and absence of GF120918. For incubations in 
the presence of GF120918, the inhibitor was added to both chambers. 3H-amprenavir, 
3H-loperamide, 3H-digoxin or 3H-quinidine was added to each corresponding drug 
concentration to allow quantification of transport from donor to receiver chambers in 
both directions over time in the presence and absence of GF120918. In addition, 100 µM 
Lucifer yellow was added to monitor cell monolayer integrity. At the indicated time 
points, 25 µL samples were taken from both these chambers and counted by TopCount 
Model 19912. 
2.2.4 Kinetic Model of Transport across a Confluent Cell Monolayer 
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The basic structural mass action kinetic model is depicted in Fig.1 and Eq 1, 2A and 2B. 
Important components of the model are: passive permeability across the lipid bilayers; 
partitioning of substrates into the membranes; active transport by P-gp and other 
transporters.  Active transport by P-gp occurs uni-directionally, with substrate binding to 
a site on P-gp in the apical membrane inner monolayer and with efflux into the apical 
chamber.  The simplest Michaelis-Menten mass action reaction to model active P-gp 
transport is shown in Equation 1. In this “P-gp only” model, the elementary rate 
constants are simultaneously fitted to mass action equations for P-gp mediated transport 
and passive permeability. Importantly, the P-gp surface density is an explicit mass action 
variable and fitted along with other parameters. The elementary rate constants define the 
binding constant of the substrate to P-gp from the membrane (KC=k1/kr), not the cytosol. 
The on rate constant, efflux active P-gp surface density, efflux rate constant and partition 
coefficient together give the molecular Km=((kr+k2)/k1) * KPC, from the cytosol, and 
Vmax=k2T(0) for P-gp transport.  Our kinetic analysis uses transport data from multiple 
initial drug concentrations and time points until the final steady state is approached, 
which is when concentrations in donor and receiver chamber no longer change, to fit the 
elementary rate constants for each new drug.  
In addition, our model can kinetically detect the presence of other transporters 
contributing to the total P-gp mediated transport (reference).  We used facilitated 
transporter models for additional transporters to allow the mass action kinetics a degree 
of freedom to determine transport directionality based on the fits. According to our 
previous data, the fits are consistent with an active uptake or bidirectional transporter 
(Agnani et al., 2011). Each transporter was characterized by a single bidirectional first-
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order kinetic clearance. They are denoted as AT, for apical uptake transporter, and BT, 
for basolateral uptake transporter, Eq (2). 
                                                     AkAC AT C ATC+ ←→ +                                    2(A)                                        
                                                     BkB CC BT C BT+ ←→ +                                    2(B)                                            
It is possible that more than one transporter is involved at these membranes. In that case, 
we would be fitting some weighted average. Importantly, P-gp mediated transport was 
not estimated by simply subtracting the +918 transport from the total transport, which 
does not take back flow into consideration. Instead, passive permeability coefficients 
over time were included within the mass action differential equations and fixed by the 
time-dependent +918 experiments.  
Lipid bilayer partition coefficients are used to define the free concentrations within the 
aqueous compartment that is bound by the lipid membrane (Lumen et al., 2013; Tran et 
al., 2005).  Partition coefficients were fixed at the values shown in Table 1. The 
differential equations were solved in MATLAB 2014b using the ODE23s solver. 
 
2.2.5 Data analysis using particle swarm 
The particle swarm program was used to fit the elementary rate parameters for our data 
sets.  All the applicable data is fitted simultaneously. All kinetic parameters were free to 
range during the fitting.  The “goodness of fit” to a particular drug data set was 
quantified by the coefficient of variation (CV) calculated between model simulations and 
the experimentally measured kinetic data. T(0) was fitted as a consensus for all the data 
(Agnani et al 2011).  
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2.3 Results 
P-gp mediated transport across Caco-2 cell monolayers was measured for amprenavir, 
quinidine, loperamide and digoxin over 6 hours in both B>A and A>B directions in the 
absence and presence of using a range of initial concentrations and both in the absence 
and presence of GF120918.  For each concentration and transport direction, 
concentration versus time curves were generated in triplicate for both donor and receiver 
chambers.  The first time point taken was after 6 min and this time point was used as the 
starting point for fitting to eliminate the need to correct for initial transient effects (Tran 
et al., 2004). For each drug, the number of initial concentrations varied: 6 data sets were 
generated for amprenavir, with initial concentrations between 0.2~50 μM; 5 data sets for 
quinidine with concentrations between 0.1~30 μM; 6 data sets for loperamide with 
concentrations between 0.1~30 μM; and 5 data sets for digoxin with concentrations 
between 0.1~10 μM.  Each concentration versus time curve has 9 time points ending at 6 
h: 6 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6 h. Therefore, each concentration 
yields 36 data points.  
In our model, we explicitly fit passive permeability coefficients when P-gp is fully 
inhibited by GF120918 and then use those parameters in the fitting of the total transport, 
when P-gp is active.  
This method is more accurate than simply subtracting the passive transport data curve 
from the total transport data curve since in the latter case possible backflow is ignored 
(Tran et al., 2005). Regarding other transporters, it is possible that some of them are not 
inhibited by GF120918. In that case, the calculated +GF120918 passive permeability 
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would include their contribution, in addition to the passive lipid bilayer permeability. 
The steady-state values for the +GF120918 passive permeability coefficients are shown 
in Table 1. 
 
2.3.1 Fitting the drug independent values: T(0) and k1  
Previously, we found that the efflux active P-gp surface density T(0) in confluent 
MDCKII-hMDR1 cell monolayers was independent of which drug was being transported.  
This is as expected since the same MDCK cell line was used to measure transport of each 
drug (Agnani et al., 2011; Tran et al., 2005). The association rate constant, k1 was also 
drug independent, which was not anticipated, and was on the order of the maximal 
diffusion rate of a drug like compound in a lipid bilayers. This is consistent with the fact 
that the P-gp binding site is large compared to the molecular size of the drugs we studied 
(Aller et al., 2009). In essence a drug is able to access the P-gp binding site on its first or 
second encounter with the transporter. Assuming that T(0) and k1 would be also drug 
independent in Caco-2 cell line for the same reasons as outlined above, we first fitted T(0) 
and k1 to consensus values for all data obtained with the Caco-2 cell line, while assuming 
that each drug had a drug specific kr and k2 value and P-gp was the only transporter 
involved. The drug specific kinetic parameters were then fitted using just the specific 
drug datasets, e.g. the amprenavir specific kinetic parameters kr and k2 were fitted using 
only amprenavir datasets. The upper and lower bound for the kinetic rate constants and 
efflux active P-gp surface density were the same as in Agnani et.al.(Agnani et al., 2011). 
However, fitting beyond the boundary was allowed for a better fit, except for T(0), which 
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was constrained at the upper boundary based on the maximal P-gp surface density 
attainable for closely packed P-gp.   
Table 1B contains the consensus fits for the kinetic parameters in Caco-2 cells. The 
consensus fits for the kinetic parameters in MDCKII-hMDR1 are included for 
comparison (Table 1A) (Lumen et al., 2013) . Each outcome in Table 1A and 1B is 
shown as the average with standard deviation from 6 independent fittings. The small 
standard deviations of the T(0) and k1 values suggest that a good consensus fit was 
obtained by simultaneously fitting transport data from the four drugs used in this work. 
This is a benchmark for our fitting approach as the same cell line is used for each drug 
and there is only one species of P-gp. In addition, the fitted efflux active P-gp in pmol 
per transwell was also shown in Table 1. Efflux active P-gp surface density was 
converted from efflux active P-gp per transwell (Tran et al., 2005). The value for k1 is the 
same in Caco-2 and MDCKII-hMDR1 cells, while T(0) is 4.4 fold lower in the Caco-2 
cells. 
 
2.3.2 Fitting the drug dependent values kr and k2  
 
We next fitted the drug dependent kinetic parameters, kr and k2. T(0) and k1 were fixed at 
their consensus values (Table 1B) and kr and k2 were obtained in 6 independent replicate 
fits for each drug. For this first round of fitting, we assumed that no other transporter was 
involved in transcellular transport. Then the data sets were fitted again, allowing a 
bidirectional basolateral transporter, a bidirectional apical transporter, or both in the 
model. The assessment of whether a basolateral or apical transporter plays a role is then 
based on improvement in the fits. The goodness of fit is based on the coefficient of 
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variation (CV) between data and fit. Our criteria for a good fit is a CV ≤ 0.03 (Tran et al., 
2005).  If incorporation of an additional transporter results in a 25% improvement in the 
CV, then the additional transporter is considered to play a kinetically important role. 
Amprenavir and quinidine transport data was well fitted with just kr and k2. The CV for 
the fit to the amprenavir and quinidine data was 0.027 and 0.019, respectively (Table 3). 
No significant improvement was observed in the fits by adding additional uptake 
transporters in the model. These two compounds do not show any kinetic need for other 
uptake transporters. Figure 2A and 2B show the experimental concentration versus time 
curves for 2µM amprenavir and 1µM quinidine in both donor and receiver chambers as 
well as the fits to the data. The solid lines indicate the fits to the data using the values for 
from Table 1B. The values for kr and k2 can be found in Table 1B for Caco-2 cells and 
1A for MDCK-hMDR1 cells. The values are very similar in both cell systems. 
For digoxin and loperamide we found that the CV improved by 89% and 30% 
respectively when a basolateral uptake transporter was allowed in the model (Table 3). 
Figure 3A shows that for 1 µM digoxin there is a substantial underestimate of the amount 
transported when only P-gp is incorporated in the model. Without a basolateral uptake 
transporter the only way for drug to get into the cells is via passive permeability.  It is 
clear from the fits that not enough digoxin is able to enter the cells by passive 
permeability alone to then be effluxed to the apical chamber. With the added basolateral 
uptake transporter very good fits to the data were obtained.  It is worth noting that in 
contrast to the MDCKII-hMDR1 cells, no significant improvement in CV was seen with 
addition of an apical transporter in the current study (Table 3).  This is likely due to the 
much shorter incubation time in this study (6 hours vs 18 hours for the MDCKII-hMDR1 
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cells) such that back transport from apical to basolateral compartment is insignificant 
(Acharya et al., 2008; Lumen et al., 2013). Similar results were obtained for loperamide 
(Figure 3B), but the effect of the basolateral uptake transporter is much less evident.  The 
values for kr and k2 can be found in Table 1B for Caco-2 cells and 1A for MDCK-
hMDR1 cells.  The values are very similar in both cell systems.  The average of 
bidirectional first-order kinetic clearance of basolateral uptake transport was 35±0.7 S-1 
for digoxin and 20±0.3 S-1 for loperamide.  In both cell lines, the “P-gp only” model is 
sufficient for amprenavir and quinidine, but incorporation of a basolateral uptake 
transporter was required for both digoxin and loperamide.   
The efflux active P-gp surface density was 4.4 fold greater in the MDCK-hMDR1 cells 
than in Caco-2 cells.  We measured P-gp mRNA expression in MDCKII-hMDR1 and 
Caco-2 cells by by quantitative RT-PCR. Table 2 shows that the P-gp mRNA expression 
level was about 7 fold higher in MDCKII-hMDR1 than in Caco-2 cells. This is consistent 
with the higher efflux active P-gp surface density in these cells. 
 
2.4 Discussion  
Middle out or bottom up mechanistic PBPK models of transporter based DDI data ideally 
use transporter specific and system independent in vitro kinetic parameters for transport 
and transport inhibition as well as scaling factors for active transporter levels (Huang et 
al., 2013; Jones et al., 2015).  In reality however, these PBPK models currently also often 
require compound specific scaling factors to generate a good fit to the data, and thus 
loose a level of mechanistic content.  This is compounded by the lack of transporter 
specific substrates and inhibitors.  The physical nature of these compound specific 
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scaling factors is generally not understood.  Possible reasons for the disconnect are: (1) 
the structure of the PBPK model itself or (2) total transporter levels measured in vitro 
and in vivo do not equal active transporter (3) in vitro kinetic parameters are dependent 
on the in vitro system in which they are generated and can therefore not be extrapolated 
to the in vivo situation.  
We have previously shown that P-gp substrates with relatively low passive permeability 
such as digoxin, loperamide and vinblastine kinetically require basolateral uptake 
transport over that allowed by passive permeability, while highly permeable P-gp 
substrates such as amprenavir, quinidine, ketoconazole and verapamil do not (Lumen et 
al., 2013).  When an unidentified basolateral uptake transporter is involved in transport of 
a compound across a polarized cell monolayer, the kinetic parameters determined using 
this system (Km, IC50) are a convolution of transport by or inhibition of both 
transporters. These parameters are dependent on the in vitro system in which they were 
generated and mechanistic extrapolation from in vitro to in vivo becomes questionable. 
Kinetic analysis of P-gp mediated transport is typically based on the steady-state 
Michaelis-Menten analysis.  Bentz and Tran et al. first showed by simulation that the Km 
for P-gp fitted using steady-state Michaelis-Menten kinetic analysis of intracellular 
concentrations could be up to three orders of magnitude smaller than the biochemically 
predicted Km (Bentz, Tran, Polli, Ayrton, & Ellens, 2005). There are two possible 
reasons for this.  First of all, the Michaelis-Menten Km is in fact a convolution of three 
parameters: KB (binding constant of the substrate to P-gp from the inner monolayer of 
the apical membrane), KPC (partition coefficient of the substrate between the inner 
monolayer of the apical membrane and the cytosol of the cell) and passive permeability 
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coefficient of the substrate across the confluent cell monolayer.  Secondly, the Michaelis-
Menten derivation is specifically based on the fact that the concentration of substrate at 
the binding site does not change.  This is easy to establish for the substrate of an enzyme 
in solution, but not for a transport process via a transporter like P-pg, with a substrate 
binding site within the inner apical monolayer and the relevant substrate concentration 
within the cell.  In fact, simulations have shown that that intracellular concentrations for 
Pgp substrates change as a function of time, especially at early time points (Lumen et al., 
2010).  So there is no mathematical basis for application of Michaelis-Menten kinetic 
principles to P-gp mediated transport and therefore the meaning of the apparent Km 
generated by this method remains somewhat obscure. 
When Michaelis-Menten steady state kinetics are applied to P-gp mediated transport 
across polarized cells it is typically assumed that P-gp is the only transporter involved in 
the transport process.  If another transporter is involved, than the Km becomes a 
convolution of both transport processes. In other words, the Km value obtained becomes 
system dependent and translation to in vivo may be flawed, unless the contribution of the 
other transport process is explicitly recognized. Our ultimate goal is to obtain kinetic 
parameters for P-gp mediated drug transport in vitro which can then be used in PBPK 
models, combined with scaled values for transporter expression levels, to predict drug 
concentrations in tissues.    
In the Michaelis-Menten steady state analysis, the mass action kinetic equation for 
transport can be solved algebraically when considering initial rate data only.  In the 
structurally based mass action kinetic model we developed for P-gp transport, the kinetic 
analysis is not limited to initial rates, but in fact relies on approaching a final steady state 
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for transport, i.e. until the concentrations of drug in donor and receiver chamber no 
longer change. In this case the mass action kinetic equations for transport are solved by 
numerical integration coupled with Global Optimization to obtain the elementary rate 
constants governing P-gp transport as well as the efflux active P-gp surface density. This 
model has been validated using transport data across confluent MDCKII-hMDR1 cell 
monolayers for several compounds.   
The model can be used as a diagnostic tool to detect contribution from other transporters 
in addition to P-gp (Lumen et al., 2013).  These authors showed that the transport 
kinetics of the relatively low permeability drugs digoxin, vinblastine and loperamde 
require an uptake transporter, but the kinetics of the high permeability drugs amprenavir, 
quinidine and ketoconazole do not.  This demonstrates that for compounds with a passive 
permeability value in MDCK-hMDR1 cells of ≤ 320 nm/s, it is quite possible that an 
uptake transporter contributes to the overall kinetics. 
In order to determine if the fitted elementary rate constants from the structural model can 
be directly extrapolated to other systems (i.e. without scaling factors), we determined 
these rate constants in a second cell line, Caco-2. As is shown in Tables 1A and 1B, the 
P-gp specific elementary rate constants fitted for transport of amprenavir, quinidine, 
loperamide and digoxin across Caco-2 cells are very similar to those obtained in 
MDCKII-hMDR1 cells. Since MDCKII-hMDR1 and Caco-2 cells are both mammalian 
cells which very likely have similar plasma membrane composition, it is not surprising 
that the association rate constant to P-gp, which depends on lateral diffusion of the 
substrate in the lipid bilayer and the size of the binding pocket on P-gp, is the same in the 
two cell lines (van Meer, Voelker, & Feigenson, 2008). P-gp is an ATP-dependent efflux 
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pump. To date, the maximal ATP hydrolysis rate found for lipid reconstituted or 
detergent solubilized P-gp is on the order of 10-20 s-1 (Loo & Clarke, 2000; Urbatsch, 
Tyndall, Tombline, & Senior, 2003). The highest efflux rate constant in Caco-2 and 
MDCK cells was fitted for amprenavir and ranged from 10 s-1 in Caco-2 cells to 30 s-1 in 
MDCK cells, in good agreement with the biochemically measured hydrolysis rate. The 
dissociation rate constants are very similar in two cell lines, resulting in a low binding 
constants in both cell lines, consistent with broad substrate specificity.  
As for MDCK-hMDR1 cells, Caco-2 cells showed a kinetic requirement for a basolateral 
uptake transporter for digoxin and loperamide (Acharya et al., 2008; Agnani et al., 2011).  
Since the identity of these uptake transporters, or their expression level, is not known, a 
comparison of the first order rate constants for digoxin and loperamide between the two 
cell lines is meaningless.   
It has been claimed recently that the unstirred water layer (UWL) should be accounted 
for when measuring transport kinetics using cultured cell systems. Otherwise, the 
apparent affinity of the substrate to the transporters may be underestimated (Shibayama 
et al., 2015). In our model, since the passive permeability was fitted when P-gp is fully 
inhibited by GF120918, any effect of UWL will be included in the passive permeability 
coefficient. As a result, our fitted elementary rate constants for P-gp active transport will 
not be biased due to the effect of UWL.   
An important difference between the structural model and the compartmental models 
based on Michaelis-Menten analysis is that in the structural model P-gp is treated as an 
explicit chemical species, rather than being embedded in the Vmax or represented by a 
rate-constant between compartments. The efflux active P-gp surface density is an 
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important variable of the model, fitted along with the elementary rate constants. The term 
“efflux active” indicates that our kinetic analysis does not measure total plasma 
membrane P-gp, but only measures those P-gp molecules that efflux drug into apical 
chamber. Our fitted efflux active P-gp surface density (T0) in Caco-2 cells is 4.4-fold 
lower compared to MDCKII-hMDR1 cells. This result was as expected since a similar 
fold difference between MDCK and Caco-2 cells was observed in Lumen et al.(Lumen et 
al., 2013). This difference can be due to a lower total P-gp expression level in the Caco-2 
cells.  This explanation is reasonable as a 7 fold lower mRNA expression was observed 
in Caco-2 cells compared to MDCKII-hMDR1 cells.  In addition, several papers have 
shown that MDCKII-hMDR1 cells have a higher level of total P-gp than Caco-2 cells 
(Tang, Horie, & Borchardt, 2002; Taub, Podila, Ely, & Almeida, 2005).  It is also 
possible that the level of total P-gp is the same in both cell lines, but that a greater 
fraction of Pgp on MDCK cells is efflux active due to a difference in morphology of 
microvilli between the two cell lines.  Caco-2 cells possess longer and more densely 
packed microvilli than MDCK cells (Butor & Davoust, 1992; Gill et al., 2008; Nicolaou 
et al., 2012).  We have speculated previously that for the packed microvilli, like Caco-2 
cells, the efflux into the apical chamber happens only from P-gp at the tips of the 
microvilli (Tran et al., 2005). Drug released from P-gp at the base of a microvillus would 
randomly diffuse through the aqueous space between microvilli and partition into the 
apical membrane again, as though the molecule had never been effluxed. In this case the 
efflux active P-gp is a fraction of the total plasma membrane P-gp.  The fraction of efflux 
active Pgp will depend on the morphology of the microvilli and be greater on cells with 
shorter or less densely packed microvilli, such as MDCK cells.  
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2.5 Conclusion  
The best parameters for incorporation into mechanistic PBPK models for transporters are 
system independent kinetic parameters and active (not necessarily “total”) transporter 
levels. The elementary rate constants for transport by P-gp (on-, off- and efflux rate 
constants: k1, kr and k2) are very similar for P-gp expressed in Caco-2 cells versus 
MDCK-hMDR1 cells and are therefore independent of the in vitro system in which they 
are generated.  This cannot be assumed a priori for Km values generated using the 
Michaelis-Menten approach. There are two reasons for this.  First of all it is very difficult 
to establish for P-gp that the condition of no change in substrate concentration at the 
binding site during the initial transport phase is satisfied. This is the mathematical basis 
for the Michaelis-Menten analysis.  Secondly, for compounds with lower passive 
permeability, it is quite possible that an uptake transporter is contributing to the overall 
transport kinetics, such that the Km becomes a convolution of binding to two transporters 
and therefore system dependent.  Future work will address whether the presence and/or 
morphology of microvilli on the apical membrane of polarized cells can actually result in 
a fraction of P-gp present in the apical plasma membrane being effectively “inactive”, 
thereby potentially impacting transporter in vitro to in vivo scaling.   
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2.6 Tables and figures 
 
Figure 1: Cartoon model of polarized cells, with the apical membrane on top and the 
basolateral membrane on the bottom. Passive permeability occurs in both directions. P-
gp expressed on the apical membrane transport substrate from the inner apical membrane 
monolayer in to the apical chamber. Substrate binds to P-gp with association rate 
constant k1, dissociate from P-gp back to apical membrane with off rate constant kr, 
efflux from membrane to apical chamber with efflux rate constant k2. KA and KB are the 
first order clearance for other transporters in apical and basolateral membrane, 
respectively 
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Figure 2: Transport data of amprenavir and quinidine over 6 hours and their fitted curves 
across Caoco-2 cell monolayers. Figure 2A, 2 µM amprenavir; Figure 2B, 1 µM 
quinidine. The symbols show the data points with error bars showing the standard 
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deviation of triplicate measurements. The lines show the best fits for amprenavir and 
quinidine transport assuming there are no other transporters. A: B>A denotes the 
substrate concentration in the apical chamber when the basolateral chamber is the donor, 
while B: B>A denotes the substrate concentration remaining in the donor basolateral 
chamber. The A: B>A transport is high because P-gp actively efflux drug into the 
receiver apical chamber. The B: A>B denotes the substrate concentration in the 
basolateral chamber when apical chamber is the donor, while A: A>B denotes the 
substrate concentration remaining in the donor apical chamber.  
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Figure 3: Loperamide and digoxin B>A transport data in Caco-2 cells fitted with and 
without a basolateral transporter. Fig. 3A, 1 µM digoxin. Fig. 3B, 0.3 µM loperamide. 
The symbols show the data points with error bars showing the standard deviation of 
triplicate measurements. The fits for P-gp alone are shown by a dotted line, whereas the 
solid line shows the effect of adding a basolateral uptake transporter modeled with first-
order clearance. Both digoxin and loperamide show an underestimate of the data for P-gp 
alone at 1 µM (black arrows). 
 
 
 
 
 
 
 
 
 
 
 55
 
Table 1A: Fitted Consensus Kinetic Values for MDCK-hMDR1 Confluent Cell 
Monolayers from Lumen et al.(Lumen et al., 2013) 
 
 
 
 
 
 
 
 
 
 
Substrate  Associatio  
Efflux 
Active P-
gp 
Efflux 
Active 
Dissociati
on from 
Efflux 
From  Partition 
Passive 
Permeability  Other 
  to P-gp   
P-gp 
Surface 
 P-gp into 
Apical  
P-gp  
into 
Apical 
 
Coefficien
t  Coefficient at   Bidirectional 
       Density  Bilayer  
 
Chamber   
steady-state  
(nm/sec) 
Transporters 
(s-1) 
  k1 (M-1s-1)a 
pmol/well
b 
[P-gp] (per 
μm2)c kr (s-1)d k2 (s-1)e KPCf PBAg          PABg kBh      kAh 
Amprenav
ir (n=7) (1±0.4)x10+8         0.5±0.1 800±200          (7±3)x10+4      30±8                 100±2 420±50   350±30     0         0               
Quinidine 
(n=5) 
Same as 
above 
Same as 
above 
Same as 
above (4±2)x10+3     3±0.4              350±40 670±50   670±50     0         0              
Loperamid
e (n=7) 
Same as 
above 
Same as 
above 
Same as 
above (2±1)x10+4       0.4±0.08        1500±250 320±90   320±70     100±7 0              
Digoxin 
(n=5) 
Same as 
above 
Same as 
above 
Same as 
above (3±1)x10+4     3±1                  100±10 50±10     320±70        40±3   40±20      
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Table 1B: Fitted Consensus Kinetic Values for Caco-2 Confluent Cell Monolayers 
 
 
ak1 is the drug independent association rate constant from the membrane to P-gp. This 
value is fixed for all drugs fitted here. 
b pmol of efflux active P-gp per transwell is fixed for all drugs fitted here. 
cT(0) is the surface density of efflux active P-gp in the apical membrane inner monolayer 
for all drugs. This value is fixed for all drugs fitted here. The units P-gp/mm2 can be 
converted to mmols P-gp per liter of inner apical membrane simply by dividing by 0.8 
(Tran et al., 2005). 
dkr is the dissociation rate constant from the P-gp binding site into the apical bilayer.  
ek2 is the efflux rate constant from the P-gp binding site into the apical chamber.  
Substrate  
Associati
o  
Efflux 
Active P-
gp 
Efflux 
Active 
Dissociation 
from 
Efflux 
From  Partition 
Passive 
Permeability  Other  
  to P-gp   
P-gp 
Surface  P-gp into Apical  
P-gp  into 
Apical 
 
Coefficien
t  Coefficient at  
 
Bidirectio
nal 
       Density  Bilayer   Chamber   
steady-state  
(nm/sec)g 
Transport
ers (s-1) 
  
k1 (M-1s-
1)a 
pmol/well
b 
[P-gp] 
(per 
μm2)c kr (s-1)d k2 (s-1)e KPCf PBAg          PABg 
kBh         
kAh 
Amprenav
ir (n=7)  1.7x10+8 0.1±0.02 180±30   (5.89±1.57)x10+4 10±0.02 100±2 437±54   418±53 0             0 
Quinidine 
(n=5) 
Same as 
above 
Same as 
above 
Same as 
above (1.1±0.01)x10+4 1.1±0.01 350±40 477±103 373±52  0            0 
Loperami
de (n=7) 
Same as 
above 
Same as 
above 
Same as 
above   (6.0±0.02)x10+4 0.26±0.01 1500±250 134±50   195±30 20±0.3   0 
Digoxin 
(n=5) 
Same as 
above 
Same as 
above 
Same as 
above  (1.95±0.3)x10+4  8.7±0.32 100±11  64±10     66±18        35±0.7    0 
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fThe partition coefficient between the cytosol and the inner plasma/apical monolayer, 
KPC(Lumen et al., 2013). Cell membrane partition coefficients were estimated using 0.1 
mm extruded unilamellar liposomes (LUV) whose lipid compositions mimic roughly the 
lipid compositions of the respective membrane monolayers: inner cytosolic PS/PE/ chol 
(1:1:1); apical outer, PC/SPH/chol; and basolateral outer, PC/chol (2:1). Only the inner 
cytosolic partition coefficient, KPC, is shown in this table. 
gPBA and PAB refers to the +GF120918 steady-state passive permeability coefficient, B>A 
and A<B respectively.  
hkB and kA refers to the 1st order rate constant for transport through a bidirectional update 
transporter.  
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Table 2: Ratio of MDCKII-hMDR1 to Caco-2 cells on efflux active P-gp surface 
density and expression of mRNA 
 
 
 
 
 
Table 3: Ratio of MDCKII-hMDR1 to Caco-2 cell on efflux active P-gp surface density 
and expression of mRNA. Efflux active P-gp surface density were fitted along with other 
elementary rate constants by mass action kinetic model in MDCKII-hMDR1 and Caco-2 
cells. mRNA level was measured by real-time PCR normalized by total RNA in 
MDCKII-hMDR1 and Caco-2 cells. 
 
 
 
 
 
 
 
 
  
Efflux Active P-gp Surface   
Density  
mRNA 
  
P-gp/ µm2 
Copies of P-gp mRNA 
/ng RNA 
MDCK-hMDR1 800±200 6748±653 
Caco-2 180±40 918±78 
Ratio of 
MDCK/Caco-2 
 ~4.4  ~7 
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Table 3: Comparison of CV when P-gp only is fitted and when additional 
transporters were allowed in the model for Caco-2 confluent cell monolayer 
Drugs Amprenavir Quinidine 
Transporters  P-gp only AT BT AT+BT P-gp only AT BT AT+BT 
CV comparison with P-
gp only   0% 1% -1%   6% -3% 3% 
CV 0.028 0.028 0.027 0.028 0.020 0.019 0.019 0.019 
Pgp/um2 176 176 176 176 176 176 176 176 
k1(M-1s-1) 1.7 x 108 1.7 x 108 1.7 x 108 1.7x 108 1.7 x 108 1.7 x 108 1.7x 108 1.7x 108 
kr(s-1) 5.9 x 104 5.3 x 104 5.9 x 104 5.4 x 104 1.1 x 104 1.1x 104 1.1 x 104 1.0 x 104 
k2(s-1) 10.0 10.1 10.0 10.1 1.1 1.5 1.1 1.4 
kA(s-1)   14.6   10.4   89.9   72.6 
kB(s-1)     0.3 1.1     9.6 2.4 
Drugs Loperamide Digoxin 
Transporters  P-gp only AT BT AT+BT P-gp only AT BT A+B 
CV comparison with P-
gp only   1% 30% 0%   1% 89% -1% 
CV 0.017 0.017 0.012 0.012 0.073 0.072 0.008 0.008 
Pgp/um2 176 176 176 176 176 176 176 176 
k1(M-1s-1) 1.7 x 108 1.7 x 108 1.7 x 108 1.7 x 108 1.7 x 108 1.7 x 108 1.7 x 108 1.7 x 108 
kr(s-1) 5.9 x 104 5.9 x 104 6.0 x 104 6.0 x 104 1.1 x 104 1.1 x 104 2.0 x 104 1.4 x 104 
k2(s-1) 0.5 0.5 0.3 0.3 8.6 8.9 8.7 8.7 
kA(s-1)   6.4   0.1   58.3   14.8 
kB(s-1)     19.6 19.4     34.2 33.7 
 
Table 3: Comparison of CV when P-gp only is fitted and when additional 
transporters were allowed in the model. CV value was first fitted assuming P-gp was 
the only transporter involved in transcellular transport. Then the data sets were fitted 
again, or allowing a bidirectional apical transporter (AT), a bidirectional basolateral 
transporter (BT), or both (AT+BT) in the model. There was no significant improvement 
of CV when fitting with additional transporters for amprenavir and quinidine. There were 
30% and 89% of improvement when an additional basolateral uptake transporter was 
allowed in the fitting for loperamide and digoxin, respectively.    
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Abstract 
From previous fits of drug transport kinetics across confluent MDCKII-hMDR1 and 
Caco-2 cell monolayers (Meng at el., 2015A), we estimated the levels of efflux active P-
gp in these two cell lines. In the present work, we compared the efflux active P-gp 
number to the total P-gp level and explored the P-gp expression-activity relationship. Our 
results show that in Caco-2 cells total P-gp is much greater than efflux active P-gp, while 
in MDCKII-hMDR1 cells the values are fairly similar. We further visualized the 
microvilli in MDCKII-hMDR1 and Caco-2 cells using three-dimensional structured 
illumination microscopy (3D SIM), a super-resolution microscopy method. We found 
that the microvilli in Caco-2 cells are taller and more densely packed than those in 
MDCK-hMDR1 cells. We speculated over 10 years ago that only P-gp at the tips of 
microvilli contribute to efflux activity, while the remainder are involved in a futile cycle 
of drug efflux from the microvillus membrane followed by reabsorption into that 
membrane, as the molecule diffuses in the direction of the tip of the microvillus, before it 
can escape into the apical chamber.  The difference between total P-gp expression levels 
and levels of efflux active P-gp in Caco-2 cells, but not (or to a much lower extent) in 
MDCK-hMDR1 cells can be explained by the difference in the  morphology of microvilli, 
which would lead to a substantial fraction of P-gp in Caco-2 cells not contributing to 
final release of drug into the apical chamber, but instead being involved in a futile cycle 
of drug efflux followed by reabsorption, while this is not the case (or to a lesser extent) 
in the less densely packed and shorter microvilli on MDCK-hMDR1 cells, allowing 
easier escape from the space between the microvilli. The effect of microvilli morphology 
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differences between in vitro and in vivo systems should be considered when scaling 
transporter activity for P-gp and possibly other efflux transporters.   
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3.1 Introduction 
It is now well established that, in addition to drug metabolizing enzymes, drug 
transporters also play a critical role in drug absorption, distribution and elimination.  
Drug transporters affect drug concentrations in tissues and cells and therefore may be an 
important determinant of drug efficacy and safety. In addition, inhibition or induction of 
transporter activity can lead to drug-drug interactions with sometimes serious 
consequences.   
Cytochrome P450-mediated hepatic drug metabolism in vivo can be predicted based on 
an in vitro measured Km and Vmax, together with an intersystem extrapolation factor 
(ISEF), which scales the in vitro Vmax to the appropriate in vivo Vmax, based on 
differences in enzyme activity in vitro and in vivo (Proctor, Tucker et al. 2004). At 
present, in vitro to in vivo extrapolation of transporter kinetic data often requires 
compound dependent scaling factors (Harwood, Neuhoff, Carlson, Warhurst, & Rostami-
Hodjegan, 2013; Zamek-Gliszczynski et al., 2013). The reasons for this are currently not 
well understood and may be multiple. Transporter kinetic parameters are typically 
generated using Michaelis-Menten approximations. Importantly, in vitro to in vivo 
extrapolation of kinetic parameters assumes that the in vitro Km is system independent 
and that the Vmax can be scaled based on transporter expression levels, rather than 
transporter activity. Experimental evidence that these assumptions are valid is typically 
lacking. 
We have demonstrated previously for P-gp that Michaelis-Menten approximations are 
not always valid when applied to drug transport (Bentz, Tran, Polli, Ayrton, & Ellens, 
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2005). We developed a structural mass action kinetic model for P-gp mediated transport 
which is also a diagnostic tool for the detection of other transporters involved in 
transcellular transport (Acharya et al., 2008; Agnani et al., 2011; Lumen et al., 2013). 
Using this model, elementary rate constants (on rate constant k1, off rate constant kr and 
efflux rate constant k2) governing binding to and efflux from P-gp were obtained for 
several substrates and have been shown to be the same in Caco-2 and MDCK-hMDR1 
cells. In addition, the structural model can explicitly estimate the efflux active P-gp level. 
We have previously estimated the pmol efflux active P-gp /cell monolayer of a transwell 
in MDCKII-hMDR1 cells and Caco-2 cell lines and shown that efflux active P-gp is 
about 5 fold higher in MDCK-hMDR1 cells compared to Caco-2 cells (Meng et al., 
2015A). With the recent development of protein quantification techniques, i.e. targeted 
liquid chromatography-tandem mass spectrometry (LC–MS/MS), absolute levels of P-gp 
in the cell membrane can now be measured (Prasad & Unadkat, 2014). This allows us to 
explore whether P-gp expression level is a good surrogate of its activity.  
In the current work we compared expression of total P-gp in Caco-2 and MDCK-hMDR1 
cell monolayers by Western blot and determined absolute amount of P-gp in these 
monolayers by LC-MS/MS. We found that the total amount of P-gp in the cell 
monolayers was the same, demonstrating a difference between total and efflux active P-
gp. In fact, in Caco-2 cells the pmol P-gp/cell monolayer of a transwell measured by LC-
MS/MS was 8-12 fold higher than the fitted efflux active P-gp, while there was good 
concordance between the measured and fitted values for MDCKII-hMDR1 cells. We 
speculated previously (Tran and Bentz et al.) that only P-gp at the tips of microvilli 
contribute to efflux activity (Tran et al., 2005). A compound effluxed at the bottom of a 
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microvillus would randomly diffuse in the aqueous space between the microvilli and be 
absorbed back into the microvillus membrane for another round of efflux. In this case, 
the morphology of microvilli could have an impact on the level of efflux active P-gp 
compared to total P-gp: the taller and denser the microvilli, the smaller the fraction of 
efflux active P-gp. We therefore visualized the microvilli in MDCKII-hMDR1 and Caco-
2 cells using three-dimensional structured illumination microscopy (3D SIM), a super-
resolution microscopy method and found that the microvilli in Caco-2 cells are taller and 
more densely packed than those in MDCK-hMDR1 cells. This finding explains why the 
level of efflux active P-gp is lower in Caco-2 cells than in MDCK-hMDR1 cells while 
their total P-gp is the same.  
Materials and Methods 
3.2 Materials/reagents 
The Madin-Darby Canine Kidney II cell line overexpressing human MDR1 (MDCK-
MDR1) was purchased from The Netherlands Cancer Institute (Amesterdam, The 
Netherlands). Caco-2 cells, which are human epithelial colorectal adenocarcinoma cells, 
were obtained from the ATCC (American Type Culture Collection). All cell culture 
reagents were from Gibco (Grand Island, NY). Transwell 12-well plates with 
polycarbonate insert (0.4 µM pore size and 12 mm in diameter) were obtained from 
Corning Life Sciences (Acton, MA). Pre-cast 7.5% Bis-Tris gels were from Bio-rad 
(Hercules, California). C219 antibody was from Signet Laboratories (Deham, MA) and 
anti-mouse IgG- HRP antibody was purchased from Dako (Glostrup, Denmark). Formic 
acid, acetonitrile (LC-MS grade), bovine serum albumin, ammonium bicarbonate 
(AMBIC), iodoacetamide (IAA) and dithiothreitol (DTT) were purchased from Sigma-
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Aldrich (Steinheim, Germany). Sequencing grade-modified trypsin was a product of 
Promega (Madison, WI). The ProteoExtract Native Membrane protein extraction kit was 
purchased from Calbiochem (Temecular, CA, USA). The synthetic P-gp peptides were 
purchased from Sigma-Aldrich (Steinheim, Germany) while their corresponding stable 
isotope-labeled (SIL) variants were purchased from BACHEM. BCA Protein Assay Kit 
was purchased from Pierce Biotechnology (Rockford, IL, USA). MRK16 antibody was 
purchased from Enzo and Alexa Fluor 594 Donkey Anti-Mouse IgG was purchased from 
Jackson Research. Alexa Fluor 488 phalloidin was purchased from Thermo Fisher 
Scientific. VECTASHIELD Antifade Mounting Medium with DAPI was purchased from 
Vector Laboratories. 
3.2.1 Cell Monolayer Culture and Membrane Protein Extraction 
 
The Madin-Darby Canine Kidney II cell line overexpressing human MDR1 (P-gp) was 
purchased from The Netherlands Cancer Institute and denoted as MDCK-hMDR1. Caco-
2 cells were obtained from the ATCC. The cells were maintained in culture media 
(DMEM supplemented with 10% Fetal Bovine Serum, 50 units/ml penicillin, 50 µg/ml 
streptomycin and 0.1 mM MEM non-essential amino acids) and were kept at 37ºC in 5% 
CO2. At 70%-80% confluency cells were washed twice with PBS and trypsinized with 
0.25% trypsin/ethylenediaminetetraacetic acid (EDTA).  MDCK-MDR1 cells were split 
twice a week at a ratio of 1:10 while Caco-2 cells were split once a week at a ratio of 
1:20. MDCK-MDR1 and Caco-2 cells were seeded on polycarbonate membrane inserts 
at a density of 2 × 105 / cm2 and 2.5 × 105 / cm2, respectively. The medium was changed 
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every 2-3 days.  MDCKII-hMDR1 cells were grown for 4 days while Caco-2 cells were 
maintained for 21 days before membrane protein extraction and immunohistochemistry.  
Membrane protein was extracted using the Calbiochem native membrane protein 
extraction kit according to the manufacturer’s suggested protocol with slight 
modifications. Briefly, cell monolayers were lysed in extraction buffer I of the extraction 
kit containing the appropriate amount of protease inhibitor cocktail. Cell monolayers 
were incubated for 10 min at +4 ºC under gentle agitation. The supernatant containing 
the cytosolic protein was removed and the respective pellets were re-suspended in 
extraction buffer II of the extraction kit with protease inhibitor cocktail. After 30 min 
incubation at +4ºC with gentle agitation, the supernatant containing the membrane 
protein was collected and stored at -80 ºC for future analysis. The exactly same 
extraction procedure using buffer II was repeated four times on the same cell monolayer 
to maximally extract the membrane protein. The same volume of extraction buffer I and 
II for per transwell was used in MDCKII-hMDR1 and Caco-2 cell lines. The sample 
from each round of extraction was combined and protein concentration was determined 
using a BCA protein assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA).  
3.2.2 Western blot 
The combined membrane protein extract from previous step was directly used in the 
Western blot without any modification of protein concentration. The same volume of 
membrane protein extract from MDCKII-hMDR1 and Caco-2 cell lines containing ten to 
thirty microgram of protein was separated on pre-cast 7.5% Bis-Tris gels (Bio-Rad, 
Hercules, CA) and transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad) 
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at 200 mA for 2 hours. After being blocked with 5% non-fat dry milk powder in TBST 
buffer (50mM Tris, pH 8.0, 150mM NaCl, 0.2% Tween-20) for 30 min, membranes were 
incubated with primary antibody C219 (Signet Laboratories, Deham, MA) against P-gp, 
diluted 1:200, at 4 °C overnight followed by washing in TBST. Membranes were further 
incubated with secondary antibody anti-mouse IgG- HRP (Dako, Glostrup, Denmark), 
diluted in 1:1000, at room temperature for 2 hours. Protein bands were visualized by 
chemiluminescence (ECL plus Western Blotting Substrate System, ThermoFisher, 
Rockford, IL), according to the manufacturer’s instruction and were developed using 
HyBlot CL film (Denville, Holliston, MA). The band intensity was quantified by 
software ImageJ (Wayne Rasband, NIH).  
3.2.3 Peptide Selection, Sample preparation and Trypsin Digestion of Membrane 
Proteins 
Two unique tryptic derived signature peptides (not present in any other known protein) 
were selected for quantification of P-gp based on previously reported criteria (Kamiie et 
al., 2008; Zolk & Fromm, 2011) and literature reports ((Miliotis et al., 2011; Zhang, Li, 
Brown, Ozer, & Lai, 2011). Selected signature peptides for P-gp were 
AGAVAEEVLAAIR (amino acid residue from 250-262) and NTTGALTTR (amino acid 
residue from 250-262) which are located at the fourth cytoplasmic loop and eighth 
cytoplasmic loop, respectively.  
An aliquot of 100 µL of extracted membrane protein from the previously discussed 
extraction procedure from each cell line was diluted 1:1 with 100mM ammonium 
bicarbonate solution in a 1.5 mL Eppendorf tube. The membrane samples then were 
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reduced using 10 mM dithiothreitol (DTT) at 50 ºC for 30 min and alkylated with 15 mM 
iodoacetamide in the dark at room temperature for 45 min to prevent the free sulfhydryls 
from reforming disulfide bonds. The samples then were delipidated by adding cold 
methanol (600 µL), chloroform (150 µL) and water (450 µL) and vortexed for 1 min 
sequentially. Subsequent centrifugation at 15,000 rpm for 5 min at 4 ºC resulted in a 
separation into a top aqueous and bottom organic layer. A very thin protein film was 
observed in the interface of the two phases. Upper aqueous layer was removed carefully 
without disturbing the protein film. 450 µl of cold methanol was added further into the 
sample and then followed by centrifugation at 15,000 rpm for 5 min at 4 ºC. Supernatant 
was discarded carefully. The pellets were briefly dried in a vacuum centrifuge. The 
pellets were re-suspended in 60 uL digestion buffer (100 mM ammonium bicarbonate 
and acetonitrile in a ratio of 9:1) by intermittent sonication on ice. After addition of 
internal standard, 0.5 pmol/µL of SIL P-gp proteotypic peptides 
(AGAVAEEV[15N113C6]LAAIR and NTTGAL[15N113C6]TTR), the samples were 
digested with trypsin (Promega, Madison, WI) (1:20, trypsin:protein) at 37 ºC overnight 
in a final volume 70 µL. The mass ratio of trypsin to protein was 1:20. The digestion was 
discontinued by addition of formic acid (3 µL, 50% v/v) and the sample was centrifuged 
at 15,000 rpm for 5 min at 4 ºC. Finally, the clear supernatant was evaporated to dryness 
using a vacuum centrifuge for 3h at 50 ºC. The samples were reconstituted in 60 µL of 
0.1% (v/v) formic acid prior to LC-MS/MS analysis. All samples were digested and 
analyzed using LC-MS/MS in duplicate. All sample preparation and digestion steps were 
formed using Protein Lobind tubes (Eppendorf, Hamburg, Germany).  
3.2.4 LC-MS/MS Analytical Method Parameters 
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LC-MS/MS analyses were conducted on an API4000 triple quadrupole mass 
spectrometer coupled with liquid chromatography system. The LC column used for 
peptide separation and elution was a 2.1×50mm C18 column (Acquity UPLC BEH C18, 
1.7 µm size beads, 130 Å pore size; Waters, Milford, MA).  Mobile phase A was water 
with 0.1% v/v formic acid and mobile phase B was 50% acetonitrile/50% isopropano. 
The chromatographic separation was achieved by a linear gradient starting from 5% B 
and progressing to 85% B over a period of 7 min. A sample volume of 10 µL was 
injected onto the LC column at a flow rate of 0.5 mL/min. The precursor-to-product 
transition for the quantification of the peptide “NTTGALTTR” represented the doubly 
charged precursor ion [M+2H]2+ (m/z 467.8) and the singly charged product y7 ion with 
m/z 719.4. Regarding peptide AGAVAEEVLAAIR, the doubly charged precursor ion 
[M+2H]2+ (m/z 635.4) gives rise to the singly charged product ions y9 with m/z 971.5. 
The instrument settings of the API4000 triple quadrupole mass spectrometer were: ion 
spray voltage, 4 kV; temperature, 400 °C; declustering potential (DP), 50V; collision 
energy (CE), 38 V; entrance potential, 10V; and collision cell exit potential (CXP), 11V. 
The calibration curve standards was prepared by spiking both the NTTGALTTR and 
AGAVAEEVLAAIR over the range of 780 pM to 50,000 pM and the SIL peptides 
(internal standard) at a fixed concentration of 50 nM into a surrogate matrix (1 µg/µL 
tryptically digested bovine serum albumin). Assay accuracy and precision were 
determined in triplicate at two different quality control concentrations of 1,000 and 
10,000 pM of peptide in surrogate matrix and then subjected to tryptic digestion. Data 
were processed by integration of the appropriate peak areas generated from the MRM 
chromatograms of either the AGAVAEEVLAAIR and NTTGALTTR peptides or the 
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corresponding stable label IS peptides using Analyst 1.4.2 (Applied Biosystems, Foster 
City, CA, USA). The peak area ratio of the peptides to the corresponding SIL peptide (y) 
was plotted against the nominal concentration. 
3.2.5 LC-MS/MS Assay  
The calibration curves were linear across the concentration range of 780 to 50,000 pM 
for both P-gp peptides with correlation coefficients (r2) of greater than 0.99 
(supplemental Figure 1). The retention time for P-gp peptide standard and SIL internal 
standard were 2.5 min for AGAVAEEVLAAIR and 1.5 min for NTTGALTTR, 
respectively. Accuracy and precision in the quantification of the quality control samples 
were acceptable (CV < 15%) at two different concentrations. Trypsin digestion time was 
chosen by determining the incubation time at which there was no further increment in the 
yield of peptide (data not shown).  Since purified P-gp protein standard is not available, 
the analytical method was based on the assumption that P-gp is completely extracted 
from the cell lysates and completely digested its corresponding peptides. 
3.2.6 Immunohistochemistry 
Cell monolayers were rinsed twice with PBS before being fixed with 3% w/v 
paraformaldehyde for 15 min. The fixed cell monolayers were permeabilized using 0.1% 
v/v Triton x-100 in PBS for 15 min and rinsed with PBS. Samples were blocked for 30 
min with 2% w/v bovine serum albumin (BSA) in PBS to prevent non-specific binding. 
Then, samples were incubated with primary mouse anti-human MDR1 antibodies: 5 
µg/ml MRK16 in blocking solution for 2 h at room temperature. Cells were rinsed and 
washed three times with blocking solution to remove unbound primary antibody. Cells 
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were further incubated with a solution of the secondary Alexa Fluor 594-labelled donkey 
anti-mouse IgG (1:100) in blocking buffer for 1 h, followed by Alexa Fluor 488 
phalloidin staining of F-actin for 30 min. Inserts were washed with PBS before the filter 
was excised and mounted on a slide using VECTASHIELD Antifade Mounting Medium 
with DAPI.  
3.2.7 3D structured illumination microscopy 
Super-resolution imaging was performed using the DeltaVision OMX V4 (GE 
Healthcare) microscope with a PlanApoN 60×/1.42 N objective (Olympus) and 
immersion oil with a refractive index of 1.516. Alexa Fluor 488 was excited by a 488 nm 
solid-state laser and its fluorescence emission collected between 504 and 552 nm. Alexa 
Fluor 594 was excited by a 568 nm solid-state laser and its fluorescence emission 
collected between 590 and 628 nm. A z-step size of 0.125 µm was used and images were 
sequentially acquired with sCMOS PCO.edge cameras (PCO-Tech Inc.). Raw images 
containing 3D SIM illumination patterns were reconstructed and the channels aligned 
with softWoRx software (version 6.5.1, GE Healthcare). Channel alignments in x, y, and 
rotationally around the z-axis were obtained using predetermined shifts measured from a 
registration calibration slide. Channels were aligned in z using 100-nm Tetraspeck 
fluorescent microspheres (Thermo Fisher Scientific). Imaging settings were identical 
between MDCKII-hMDR1 and Caco-2 cells. 
3.2.8 Image analysis 
Maximum intensity projections of image stacks and orthogonal views were generated 
with FIJI/ImageJ open source imaging software (http://fiji.sc). Microvilli lengths, 
 76
diameter, and volumes were measured with the Volocity 3D analysis software (version 
6.3, PerkinElmer) using the “thresholding” and “count object” function. The settings 
used for post-acquisition analysis were identical between MDCKII-hMDR1 and Caco-2 
cells. 
3.3 Results 
 
3.3.1 Western blot 
The expression of P-gp in MDCKII-hMDR1 and Caco-2 cell monolayers was determined 
by Western blot analysis of the membrane protein extract. Figure 1A shows the Western 
blot band when identical volumes of membrane protein extract from each cell line were 
loaded. Figure 1B shows the average densitometric value of the P-gp bands from 3 
independent rounds when the sample loading volumes are 40 μL. The results indicate 
that MDCKII-hMDR1 and Caco-2 cells contain the same amount of P-gp in 40 μL of 
membrane protein extract. Because the same volume of extraction buffer was used in the 
two cell lines during membrane protein extraction on cell monolayer of a single transwell, 
the results also implies that the expression of P-gp per cell monolayer of a transwell were 
the same in the two cell lines. 
3.3.2 LC-MS/MS Quantification of P-gp in MDCKII-hMDR1 and Caco-2 cell 
Monolayers 
The LC-MS/MS method described above was applied for the determination of P-gp 
protein levels in the membrane fractions extracted from MDCKII-hMDR1 and Caco-2 
cell monolayers cultured for 4 days and 21 days, respectively. The specific MRM 
transitions based on the chromatographic retention time and MS spectrum were used to 
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detect and quantify the P-gp proteotypic peptide by LC-MS/MS in MRM mode. As 
shown in Table 1, the membrane P-gp was determined in two units, which are content of 
P-gp per cell monolayer of a transwell and content of P-gp per mg membrane protein. 
The first unit is corresponding to our fitted efflux active P-gp value while the second unit 
is the one commonly used in the literature. The quantification results from the two P-gp 
signature peptides were close with minor difference (1.5-fold). Assuming that the 
difference was due to different degrees of trypsin digestion, the results used for 
comparison between the two cell lines in Table 2 were based on peptide 1. Consistent 
with the results from the Western blot, the expression level of P-gp level per cell 
monolayer of a transwell is very similar between the two cell lines, with a ratio of 
MDCK/Caco-2 of approximately 0.8 (Table 2).  
3.3.3 Comparison of efflux active P-gp with total P-gp in MDCKII-hMDR1 and 
Caco-2 cells 
Table 2 shows the ratio of total P-gp per cell monolayer of a transwell between MDCKII-
hMDR1 and Caco-2 cells was about 0.8 determined by LC-MS/MS. In addition, the 
fitted efflux active P-gp (pmol/cell monolayer of a transwell ), which were obtained from 
Lumen et al.(Lumen et al., 2013) and Meng et al. (Meng et al. 2015A), was also shown 
in Table 2. Fitted efflux active P-gp was about 5 fold higher in MDCK-hMDR1 cells than 
in Caco-2 cells. Table 2 also shows that total P-gp in Caco-2 cells is 8-12 fold greater 
than efflux active P-gp, while the values in MDCKII-hMDR1 cells are similar. 
3.3.4 Characterization of microvillus morphology in MDCKII-hMDR1 and Caco-2 
cells 
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Since our kinetic analysis only measures those P-gp that efflux drug into apical chamber, 
which were defined as “efflux active P-gp”, we hypothesized that only the P-gp 
expressed at the tip of microvilli are efflux active. If this is the case, morphology and 
density of microvilli may have a significant impact on the fraction of P-gp that is efflux 
active. We therefore investigated the morphology of microvilli on MDCK and Caco-2 
cells, grown in transwells under the exact same conditions as used for the P-gp transport 
experiments, using super-resolution microscopy (Figure 2).  Microvilli are visualized 
through staining of actin with phalloidin, while P-gp is visualized through staining with 
fluorescent antibody (Figure 2).  Microvilli on Caco-2 cells were more densely packed 
and more regularly shaped than on MDCKII-hMDR1 cells (Figure 2A and 2B).  In 
addition, some of the microvilli of MDCKII-hMDR1 cells were bended rather than all 
standing straightly as seen in Caco-2 cells. As expected, P-gp was not found in the 
cytoplasm but localized almost exclusively in the apical microvillus region of the cells 
(data not shown). In addition, it is clear that P-gp expression level varies from cell to cell 
in both cell lines, as has been observed previously in Caco-2 cells (Anderle et al., 1998; 
Hunter, Jepson, Tsuruo, Simmons, & Hirst, 1993).  Fig. 2C, 2D and 2E show the average 
length, diameter and volume of microvilli on Caco-2 and MDCKII-hMDR1 cells, 
obtained from 3D reconstitutions of microvilli using the Volocity software. The 
microvilli on Caco-2 cells are significantly longer, with a smaller diameter, than 
microvilli on MDCK cells. Fluorescence intensity profile plots in Fig 2F and 2G show 
the distribution of actin and P-gp, relative to one another on Caco-2 and MDCK-hMDR1 
cells. Actin and P-gp share similar distribution pattern as seen in Fig 2G while actin 
appears about 0.3 μm earlier than P-gp from the side of microvilli base. Some of the P-gp 
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found at the tips on the microvilli in Fig 2A appears beyond the actin in the microvilli.  
This is also reflected in Fig.2F.  Figure 2F and 2G demonstrate that Pgp is evenly 
expressed along the length of the microvillus. 
 
3.4 Discussion  
The lack of transporter specific probe substrates and inhibitors hampers clinical 
investigation of the contributions of individual transporters to drug ADME and 
mechanistic extrapolation to the ADME of other transporter substrates or inhibitor drugs.  
Physiologically based pharmacokinetic modeling is increasingly used as a tool to probe 
the role of transporters in drug disposition. Kinetic parameters for drug-transporter 
interaction (Km and Vmax) are determined in vitro, either using primary cells (i.e. 
hepatocytes) or single transporter over-expressing cells. The rate of transporter-mediated 
clearance (Vmax/Km) in vivo is then predicted by scaling the Vmax based on relative 
transporter expression levels in vitro and in vivo. This assumes Km is the same in vitro vs 
in vivo and that the total transporter levels in vitro and in vivo represent active 
transporter only. We have discussed previously the potential pitfalls in assuming the 
Michaelis-Menten Km is system independent. Here we further investigate for the first 
time the assumption that total transporter equals efflux active transporter. Recently, 
Kumar et al. reported that transport activity of BCRP expressed in MDCK cells was 
highly correlated with protein expression level (Kumar et al., 2015), but this study could 
not address the scaling of this data to different cell types.   
We have previously fitted efflux active P-gp in MDCKII-hMDR1 and Caco-2 cells using 
a structural mass action kinetic model (Agnani et al., 2011; Lumen et al., 2013; Tran et 
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al., 2005) and demonstrated that the efflux active P-gp per cell monolayer of a transwell 
was about 5 fold greater in MDCKII-hMDR1 than in Caco-2 cells. In order to investigate 
the relationship between total P-gp and efflux active P-gp, we first compared total P-gp 
level in these two cell lines by Western blot and our results implied that the total P-gp per 
cell monolayer of a transwell is very similar between MDCKII-hMDR1 and Caco-2 cell 
lines (p>0.05).  
Since Western blots were only semi-quantitative due to the unavailability of pure P-gp 
protein, total P-gp level was further quantified using liquid chromatography-tandem mass 
spectrometry (LC–MS/MS) based targeted proteomics, which has shown to be a 
promising approach for the determination of absolute level of transporter protein (Prasad 
& Unadkat, 2014). Here, two unique P-gp signature peptides were selected for the 
quantification. From the results as shown in Table 1, we observed a minor (up to 1.5-fold) 
but systematic difference (p=0.023 in both MDCK and Caco-2) in P-gp quantification 
between two different signature peptides. Since peptide AGAVAEEVLAAIR yielded the 
higher amount of P-gp in both cell lines we assume that this difference was due to 
different degrees of trypsin digestion. Therefore, the results that are used for comparison 
of absolute amounts of P-gp in the two cell lines are based on peptide 
AGAVAEEVLAAIR. In agreement with the Western blot results, the pmol P-gp per cell 
monolayer of a transwell is very similar between the two cell lines. We also calculated 
pmol P-gp per mg membrane protein, which is a unit commonly used in the literature. 
Our results are comparable to reported literature values (Miliotis et al., 2011; Zhang et al., 
2011).  The total pmol P-gp per cell monolayer of a transwell measured by LC-MS/MS is 
8-12 times greater than the fitted efflux active pmol P-gp per cell monolayer of a 
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transwell for Caco-2 cells and very similar for MDCKII-hMDR1 cells. This result 
implies that at least for Caco-2 cells, not all of the P-gp are kinetically active.  
Kits used for isolation of membrane proteins such as used in the current work do not 
distinguish between plasma membrane and intracellular membranes. Although several 
commercial kits claim to isolate plasma membrane protein, it has been shown recently 
that these kits either yields very little plasma membrane or fails to separate plasma 
membrane from other intracellular membrane (Kumar et al., 2015). In our calculations 
we assume that all P-gp extracted from the MDCKII-hMDR1 and Caco-2 cells was 
present in the apical membrane. Although P-gp has been found in intracellular 
membranes in certain cell lines (Arancia, Molinari, Calcabrini, Meschini, & Cianfriglia, 
2001), it has shown to be almost exclusively expressed in the apical membrane of 
MDCK and Caco-2 cells (Anderle et al., 1998; Hutter et al., 2014).  Evidence for this 
was also obtained in our Caco-2 and MDCKII-hMDR1 micrographs, where P-gp staining 
was essentially limited to the apical membrane (data not shown). Therefore the 
difference between total and efflux active P-gp in Caco-2 cells cannot be explained by a 
large proportion of P-gp being localized intracellularly. 
Tran and Mittal et al. (2005) first hypothesized that only the P-gp at the tip of microvilli 
is efflux active (Tran et al., 2005). If this is true, the fraction of efflux active P-gp would 
be affected by the morphology of microvilli: the taller and more densely packed the 
microvilli, the smaller the fraction of efflux active P-gp. Using super-resolution 
microscopy to visualize microvilli (via staining for actin) we demonstrated that Caco-2 
cells have taller and more densely packed microvilli than MDCKII-hMDR1 cells.  
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This is consistent with published electron micrographs of Caco-2 and MDCK cells 
(Butor & Davoust, 1992; Gill et al., 2008; Nicolaou et al., 2012). Using super-resolution 
microscopy it is possible to obtain data on multiple proteins in the same image. In 
addition to visualization of actin in microvilli, we also visualized P-gp through staining 
with fluorescent antibody. P-gp is distributed in the apical membrane and spread evenly 
across the microvilli membrane. Differently from in MDCK-hMDR1 cells where actin 
and P-gp appear synchronously from the cytoplasmic side of microvilli (Fig.2G), a 
0.3μm of disconnect was observed in Caco-2 cells (Fig.2F). This disconnect could be due 
to that P-gp is expressed on the membrane of microvilli while some of the actin bundle in 
microvilli extend below the apical membrane. To our knowledge, this is the first time 
showing of distribution of P-gp by microscopy at such high magnifications. The 
microscopy data is consistent with the hypothesis that the difference between total and 
efflux active P-gp in Caco-2 cells is due to microvilli morphology.  
P-gp is an ATP binding cassette transporter and uses the energy from ATP binding and 
hydrolysis to efflux its substrate. One may argue that the difference between efflux active 
P-gp and total P-gp can be due to different ATP concentration and regulation in the two 
cell lines. However, this cannot be true because in our companion paper (Meng et al., 
2015A) we showed that the efflux rate constants of P-gp, which reflect the activity of 
ATP, were very similar between MDCKII-hMDR1 and Caco-2 cells. In addition, since it 
was observed from Figure 2A&B that P-gp spread out quite evenly along the microvilli 
rather than being clumped on particular spots of microvilli, it is unlikely that the 
difference is due to the different localization pattern of P-gp on microvilli. Therefore, the 
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most likely explanation to the different number of efflux active P-gp is the different 
morphology of microvilli in the two cell lines. 
As mentioned above, protein expression is assumed to be the closest surrogate of 
transporter activity and commonly used as a scaling factor for Vmax. However, we have 
demonstrated that the level of efflux active P-gp can be affected by morphology of 
microvilli. That is to say, the extrapolation of Vmax with this scaling method should be 
used between two cell lines with similar microvilli structure. For example, the microvilli 
morphology of MDCKII-hMDR1 cells we observed here is similar to the one in bile 
canaliculi from mouse liver (Crawford et al., 1997) and quite different from the one in 
intestinal epithelium of guinea pigs (Takeuchi & Sprinz, 1967). The scaling of Vmax using 
expression-activity method would be more accurate when the extrapolation is from 
MDCKII-hMDR1 cells to bile canaliculi than to small intestinal cells in vivo.  
In conclusion, we found that in Caco-2 cells total P-gp is much greater than efflux active 
P-gp, while in MDCKII-hMDR1 cells the values are fairly similar. The most likely 
reason for this is a significant difference in microvilli morphology between the two cell 
lines.  While P-gp is evenly distributed along the entire microvilli membrane in both cell 
types, the microvilli in Caco-2 cells are taller and more densely packed than those in 
MDCKII-hMDR1 cells, leading to a substantial fraction of P-gp in Caco-2 cells not 
contributing to final release of drug into the apical chamber, but instead being involved 
in a futile cycle of drug efflux followed by reabsorption. The effect of microvilli 
morphology differences between in vitro and in vivo systems should be considered when 
scaling transporter activity for P-gp and possibly other efflux transporters.   
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3.5 Figures and tables 
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Figure 1 Comparison of P-gp expression in confluent MDCKII-hMDR1 and Caco-2 
cells monolayer. In (A), lane 1 and lane 3, MDCKII-hMDR1; lane 2 and lane 4, Caco-2. 
Land 1 and 2 contain 40 µL of membrane protein extract while land 3 and land 4 contain 
20 µL of membrane protein extract. In (B), densitometric values of Western blot bands 
from 40 µL of membrane protein extract were quantified by ImageJ and the means ± 
SEM were from three independent experiments. Expression of P-gp protein of 40 µL 
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membrane protein extract was almost the same between MDCKII-hMDR1 and Caco-2 
cells without significant difference (Student pair t test, p value =0.09) 
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Table 1 P-gp content as determined by LC-MS/MS in MDCKII-hMDR1 and Caco-2 cell 
monolayers. 
Value are given as mean ± s.d.; n=3 
a Content of P-gp per transwell of 12-transwell plate 
b p value from paired student t test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Peptide MDCKII-hMDR1 Caco-2 
  
pmol P-
gp/confluent 
monolayer of 
a transwellla 
pmol P-
gp/mg 
protein 
pmol P-
gp/confluent 
monolayer of a 
transwelll 
pmol P-
gp/mg 
protein 
AGAVAEEVLAAIR 
0.78 ± 0.26 5.34 ± 1.77 0.95 ± 0.27 2.80 ± 0.61 
NTTGALTTR 0.52 ± 0.17 3.58 ± 1.2 0.65 ± 0.16 1.90 ± 0.36 
p valueb 0.023 0.022 0.023 0.18 
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Table 2 Comparison of efflux active P-gp with total P-gp in MDCKII-hMDR1 and 
Caco-2 cells 
 
  Fitted efflux active  
P-gp  
Absolute Pgp levels 
by LCMSMS   
  pmol P-gp/cell 
monolayer of a 
transwell 
pmol Pgp/cell 
monolayer of a 
transwell   
MDCKII-hMDR1 0.5±0.1 0.78±0.26 
Caco-2 0.1±0.02 0.95±0.27 
Ratio 5 0.82 
 
* Referred to our companion paper (Meng et al., 2015A) for more detail.  
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Figure 2: Characterization of microvilli morphology and P-gp localization in confluent 
MDCKII-hMDR1 and Caco-2 cell monolayers by 3D SIM. Representative images of 
microvilli, as seen by F-actin staining (green), and P-gp staining (red) in MDCKII-
hMDR1 cells (B) and Caco-2 cells (A).  Left panels show the maximum intensity z-
projections; rectangle panels next to the left panels show the orthogonal  (yz) views 
obtained from the vertical yellow lines shown in the z-projections. Panels on the right are 
high magnification images obtained from the red rectangles.(C). Comparison of length, 
volume and diameter of microvilli in MDCKII-hMDR1 and Caco-2 cells, as obtained 
from 3D reconstitutions of super-resolution z-stacks. 317 and 819 microvilli were 
analyzed from 6 Caco-2 cells and 7 MDCKII-hMDR1 cells, respectively. Error 
bars represent the mean ± S.E. *, p < 0.05, **, p < 0.01, and *** p < 0.001, unpaired 
Student’s t-tests performed on averaged values per cell (n=6 and n=7 for Caco-2 cells 
and 7 MDCKII-hMDR1 cells, respectively). ). Fluorescence intensity profile plots of 
actin (green lines) and P-gp (red lines) show the localization of P-gp along the microvilli, 
as seen with actin labeling, in Caco-2 (F) and MDCKII-hMDR1 cells (G). Fluorescence 
intensity profile plots were obtained from rectangular selections such as the magnified 
orthogonal views presented in A and B. The X-axis displays the horizontal distances 
through the orthogonal views which were orientated in such a way that the extracellular 
milieu is on the right and the plasma membranes closer to the origin of the X-axis. The 
Y-axis represents the vertically averaged pixel intensity of the orthogonal views. 9  Caco-
2 and 10 MDCK-MRD1 cells were analyzed. Actin and P-gp profiles from Caco-2 and 
MDCK-MR1 cells were averaged using the maximun actin values as a reference. 
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Figure 3: Cartoon figures of Caco-2 and MDCKII-hMDR1 cells with microvilli and P-
gp (dots). Red dots represent efflux active P-gp that can send their drug directly to apical 
chamber while black dots represent kinetically inactivated P-gp. The morphology of 
microvilli were drawed roughly based on results from super-resolution microscopy as 
shown in figure 2. Microvilli of Caco-2 cells are more packed, longer and with smaller 
diameter than the ones in MDCKII-hMDR1 cells. Differently from Caco-2 cells, 
microvilli on MDCKII-hMDR1 cells are not all standing straightly and some of them are 
bended. Previouly we proposed that the drug released at the base of a microvillus will be 
interacting with the same or a neighboring microvillus and the P-gp they contain. Only 
the P-gp at the tips of the microvilli can efflux the drug directly into the apical chamber 
where it can be measured. According to this hypothesis, larger fraction of total P-gp 
Caco-2 cells 
MDCKII-hMDR1 cells 
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would be efflux active in MDCKII-hMDR1 (red dots) when the total P-gp level are 
similar among the two cell lines. 
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3.6 Supplemental materails:  
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Figure 1 Representative calibration curves over the concentration range 780 to 5000 pM 
for synthetic standard peptides AGAVAEEVLAAIR(A) and NTTGALTTR (B). The 
concentration of SIL internal standard was fixed at 50nM. Each calibration standard was 
measured in duplicate. 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 2: Western blots of P-gp expression in the membrane extraction of MDCKII-
hMDR1 and Caco-2 cells. The number in the figure represents the times of extraction. 
Four times repeats of extraction were required in MDCKII-hMDR1 cells to extract most 
of the P-gp out while three times were required in Caco-2 cells. 
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Abstract: 
From previous fits of drug transport kinetics across confluent MDCK-MDR, Caco-2 and 
CPT-B2 cell monolayers, we have shown that digoxin was not only transported by P-gp, 
but also interacted with a basolateral uptake transporter which is inhibitable by 
GF120918, cyclosporine, ketoconazole and verapamil. In this work we investigated if  
NTCP and ASBT, which are sodium dependent bile acid transporters, are digoxin uptake 
transporters. Our result show that digoxin is not a substrate of NTCP while is a weak 
substrate for ASBT. Future study is to investigate if digoxin is a substrate of Ostα-Ostβ 
transporter. 
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4.1 Introduction 
Digoxin is typically used in in vitro inhibition studies as a clinically relevant P-gp probe 
substrate due to its narrow therapeutic window and clinical drug-drug interactions 
ascribed to P-gp inhibition. Inhibition of digoxin transport is often studied using 
confluent polarized cell lines with over-expression of high levels of P-gp such as 
MDCK-MDR1-NKI (from the Netherlands Center Institute) (Polli et al., 2001), MDCK-
MDR1-NIH (from NIH), Caco-2  and LLC-PK1(from the Netherlands Cancer center) 
(Cook et al., 2010). It has long been assumed that digoxin is transported across these cell 
lines solely by P-gp and passive permeability and therefore, inhibition transport of 
digoxin is due to inhibition of P-gp alone. However, Acharya et al. first showed 
kinetically that in the MDCK-MDR1-NKI cell line digoxin was not only transported by 
P-gp, but also interacted with a GF120918 inhibitable basolateral uptake transporter(s) 
(Acharya et al., 2008). Lumen at al. extended the kinetic analysis to three additional cell 
lines, including MDCK-MDR1-NIH (National Institute of Health), Caco-2 and CPT-B2 
(Caco-2 cells with BCRP knockdown) (Lumen et al., 2013), and showed similar results 
(Lumen et al., 2013). In addition to GF120918, several other compounds, which are 
cyclosporine-A, ketoconazole and verapamil, were also found to inhibit this digoxin 
uptake transporter.  
Therefore, IC50 values for inhibition of digoxin transport in these several frequently used 
cell lines may not be a pure P-gp IC50, but a convolution of inhibition of P-gp and 
digoxin uptake transport.  
Although the putative digoxin basolateral uptake transporter has been identified 
kinetically, its identity still remains unknown (Acharya et al., 2008). Therefore, several 
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candidates transporters were proposed here for investigation and the reasons are as 
follows:  
(1) Sodium-dependent transporter  
Organic anion transporting polypeptide (OATP) transporters carry bile acids as well as 
bilirubin and numerous hormones across basolateral membrane in hepatocytes, for 
excretion in bile. Besides liver, OATPs are also expressed in many other tissues on 
basolateral and apical membranes, transporting anions, neutral and even cationic 
compounds. Although it has been reported that digoxin is a substrate for OATP2 and 
OATP4 in rats and a substrate for human liver OATP1B3 and kidney OATP4C1 (Cattori 
et al., 2000; Kullak-Ublick et al., 2001), Taub et al. showed that digoxin is not a substrate 
for OATP 1A2, OATP 1B1, OATP1B3, and OATP2B1 using OATP transfected 
HEK293 cells (Taub et al., 2011). Due to the inability to express  OATP4C1 in HEK293 
or CHO cells, the role of OATP4C1 in digoxin transport was not investigated by Taub et 
al. (Taub et al., 2011). However, importantly, for the first time, they demonstrated that 
digoxin is a substrate of a sodium-dependent transporter expressed in wild type HEK293 
cells. Therefore, in this work, two sodium-dependent transporters, whose mRNA level 
have been shown to be high in HEK293 cells (reference), were chosen as candidates for 
further study of digoxin transport. 
1) NTCP (SLC10A1): Na+-dependent Taurocholate Co-transporting Polypeptide 
NTCP belongs to the sodium/bile acid symporter family of co-transporters. Localized to 
the basolateral membranes of hepatocytes, NTCP plays a role in the hepatic sodium/bile 
acid uptake system, which functions as a substrate-specific, sodium-dependent 
transporter of both bile and non-bile organic compounds (Hagenbuch & Dawson, 2004). 
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Considering its sodium-dependent characteristic and basolateral membrane location, 
NTCP is selected as a candidate for digoxin basolateral uptake transporter here. 
2) ASBT (SLC10A2): Apical Sodium Dependent Bile Acid Transporter 
ASBT is expressed in tissues that serve to facilitate the enterohepatic circulation of bile 
acids and conserve bile acids, including the apical membrane of ileal enterocytes, 
epithelial cells lining the biliary tract (cholangiocytes), and gallbladder epithelial cells (P. 
A. Dawson, Lan, & Rao, 2009). ASBT is considered a possibility to be responsible for 
the sodium-dependent digoxin uptake. A second reason for choosing ASBT is that if it 
turns out that digoxin is not a substrate of ASBT, ASBT-MDCK cell line can serve as a 
negative control cell line to the (ASBT- OSTα-OSTβ)-MDCK cell line in the following 
experiment. 
(2) OSTα-OSTβ: Heteromeric Organic Solute Transporter  
There are reports that digoxin is transported by OSTα-OSTβ which are localized on the 
basolateral membrane of intestinal, renal, and biliary epithelial cells (Ballatori, 2005; 
Seward, Koh, Boyer, & Ballatori, 2003). These transporters export bile acid from the 
intestine to the hepatic portal blood circulation (P. A. Dawson et al., 2005). In an attempt 
to identify digoxin basolateral and apical transporters by adding prototypical 
substrate/inhibitors of known transporters, Archarya et al. showed that taurocholic acid, a 
substrate of OSTα-OSTβ, failed to inhibit transport of digoxin at concentration of 200 
µM in MDCKII-hMDR1 cells (Acharya et al., 2008). However, it is worth noting that the 
apparent Michaelis constant (Km) for taurocholic acid was reported to be 785±43 µM in 
oocytes (W. Wang, Seward, Li, Boyer, & Ballatori, 2001). Therefore, it is possible that 
the concentration of taurocholic acid used by Acharya el al. (200µM) was not high 
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enough to inhibit digoxin transporter through its uptake transporter. Thus, OSTα-OSTβ 
is still a candidate digoxin uptake transporter.  
Another important reason why the above three transporters were chosen is the structural 
similarity between digoxin and taurocholic acid (a form of bile acid). They both have a 
sterone ring in their structures (Figure 5). Figure 1 shows the major transporters involved 
in enterohepatic recycling of bile acids in red, including NTCP, ASBT and OSTα-OSTβ. 
In addition, in order to be the digoxin uptake transporter that we are looking for, it should 
be inhibitable by ketoconazole, verapamil and GF120918, as observed in Lumen et 
al.((Lumen et al., 2013)． 
 
4.2 Materials and Methods 
4.2.1 Cell Preparation and Culture Conditions: HEK293 cells were transduced in 
DMEM Ham's F-12 media containing ASBT and NTCP-BacMam virus, 0.4 mg/ml 
gentamicin, and 2mM sodium butyrate. HEK293 was transfected with NTCP and ASBT 
virus with various number of multiplicity of infection (MOI). Wild-type (WT) HEK293 
cells were maintained in DMEM Ham's F-12 media without transduction reagents. 
Transduced and untransduced cells were seeded at a density of 400,000 cells/well onto 
poly-D-lysine-coated 24-well plates and incubated at 37 ºC, 5% CO2, and 95% humidity. 
At 48 h after plating, uptake experiments were conducted.  
 
4.2.2 Sodium-Dependent Digoxin and Taurocholic acid uptake in Transfected 
HEK293 cells. Transfected cells were washed and preincubated at 37 ºC for 20 min in 
transport buffer (pH 7.4) in the presence or absence of sodium. Transport buffer 
 105 
contained 20mM HEPES, 15mM glucose, 1.25 mM MgSO4, 1.2 Mm KH2PO4, 4.7 mM 
KCl, 1.2 mM CaCl2, and 110 mM NaCl and 25 mM NaHCO3 or 110 mM C5H14CINO 
and 25mM KHCO3. The buffer without sodium was osmotically balanced using 
potassium and choline. After the removal of preincubation solution, the cells were treated 
with 400 ul of transporter buffer in the presence or absence of sodium containing 1µM 
digoxin (0.1 uM [3H] with 0.9 µM cold digoxin) or 1 µM taurocholic acid (0.2 µM [3H] 
with 0.8 µM cold taurocholic acid). Cells were incubated at 37 ºC for 30 min. 
 
4.2.3 Inhibition of NTCP-Mediated Transport by Ketoconazole and Verapamil.  
Transduced cells were pre-incubated at 37 ºC for 20 min in transport buffer in the 
presence of sodium containing ketoconazole or verapamil at concentrations of 0, 2, 5, 10, 
and 20 µM. After removal of pre-incubation solution, 400 ul of transport buffer in the 
presence of sodium containing ketoconazole and verapamil at the target concentration 
and 1 µM of digoxin ( 0.1 µM [3H] with 0.9 µM cold digoxin ) or 1 µM taurocholic acid 
(0.2 µM [3H] with 0.8 µM cold taurocholic acid ) were added to the wells. Cells were 
incubated at 37 ºC for 30 min. 
 
4.2.4 Transport and inhibition studies in MDCK-ASBT cells. Following formation of 
the tight monolayer, the cells were refed culture media containing 10mM sodium butyrate 
to induce expression of the transfected genes. Approximately 20 h later, the cell 
monolayers were washed and pre-incubated with either transport medium alone or 
transport medium supplemented with 2uM GF120918 for 20 min. For incubation in the 
presence of GF120918, the inhibitor was added to both chambers. After pre-incubation, 
 106 
medium was removed and cells were incubated at 37 °C for 60 min with Hanks' buffered 
saline solution plus 1 µM of digoxin ( 0.1 µM [3H] with 0.9 µM cold digoxin ) or 1 µM 
taurocholic acid (0.2 µM [3H] with 0.8 cold taurocholic acid ) and GF120918 added to 
the apical or basolateral chambers. Trans-cellular transport was monitored by sampling 
the contra-lateral chamber.  
 
4.2.5 Sample analysis. For uptake experiment in HEK293-ASBT and HEK293-NTCP 
cells ,  after incubation, uptake was stopped by aspirating the radiolabeled incubation 
solution and washing each well 3 times with 800 µl of ice-cold transport buffer in the 
presence or absence of sodium. Cells in each well were solubilized by 400 µl of 1 % (v/v) 
Triton X-199 and incubated at 37 °C for 30 min. For analysis of total radioactivity, the 
contents of each well were determined by liquid scintillation counting in vials containing 
Ultima Gold scintillation cocktail.  
For transport experiment in MDCK-ASBT/Ostα-Ostβ and MDCK-ASBT cells, at the end 
of incubation, 25 µl samples were taken from both apical and basolateral chambers and 
counted by TopCount Model 9912.  
 
4.3 Results and discussion 
As taurocholic acid is a potent substrate of ASBT, NTCP and Ostα-Ostβ, it was used in 
the following experiments as a positive control of digoxin transport.  
4.3.1 Evaluation of Digoxin as a Substrate of NTCP 
The uptake of 1µM digoxin and taurocholic acid was evaluated in wild-type HEK293 
cells and NTCP transfected HEK293 cells at 37 ºC. As shown in Fig. 2A, there was 
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about 2-fold increase of digoxin uptake in NTCP-transfected HEK293 cells compared to 
wild-type HEK293 cells when sodium was added. At the same time, 8-fold increased 
uptake of digoxin was observed in no sodium added group. This result suggests that the 
increased of digoxin here was sodium independent. Since NTCP is a sodium dependent 
transporter, the increased digoxin observed here in NTCP-transfected HEK293 was 
possibly not due to the expression of NTCP, but rather some other reasons. One possible 
explanation is that the transfection of NTCP induced expression of some endogenous 
sodium independent transporters in the HEK293, which happened to transport digoxin. 
Another possibility lied in the empty vector. Since we didn’t run the empty vector as a 
transfection control, this possibility cannot be ruled out.  
Compared to the minor increase of digoxin uptake in NTCP-HEK293, there was 
significantly 775-fold increase of taurocholic acid uptake when sodium was added while 
only about 6-fold increase was seen in no sodium group (Fig.2B). This result confirmed 
that taurocholic acid is a potent substrate of NTCP. The increase in sodium independent 
uptake of taurocholic acid may be due to induction of some endogenous sodium 
independent transporters in the HEK293 which transport taurocholic acid rather than 
empty vector because significantly more uptake was seen in with sodium group. 
Since another important criteria for a digoxin uptake transporter is that it should be 
inhibitable by ketoconazole and verapamil, we further evaluated if ketoconazole and 
verapamil inhibit digoxin uptake of NTCP in the presence of sodium. Due to the 
cytotoxicity of ketoconazole with concentration higher than 20 µM under our assay 
conditions, the highest concentration of ketoconazole we used in this experiment was 20 
µM. As shown in Fig. 3, it is clear that no inhibition from either ketoconazole or 
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verapamil on digoxin uptake was observed on NTCP-transfected HEK23 cells. Instead 
there appears to be an increase in transport, which we currently cannot explain. 
In summary, according to our result, digoxin is not a substrate of NTCP. 
 
4.3.2 Evaluation of Digoxin as a Substrate of ASBT 
The uptake of 1µM digoxin and taurocholic acid were evaluated in wild-type HEK293 
cells and ASBT transfected HEK293 cells at 37 ºC. After a 30-min uptake experiment,  
there was about 2.3-fold increase of digoxin uptake in ASBT-transfected HEK293 cells 
when sodium was added compared to wild-type HEK293 cells as shown in Fig.4A. It is 
worth noting that the uptake of digoxin remained almost the same in the no sodium group. 
This result suggests that the increase of digoxin uptake here is sodium dependent and 
may be due to expression ASBT. However, further experiment with no vector control 
group was needed to exclude any possible interference from the vector.  
Regarding taurocholic acid, its substantially high uptake level observed in ASBT-
HEK293 cells confirmed its identity as a potent substrate of ASBT (Fig. 4B). In addition, 
the uptake level of taurocholic acid in ASBT-HEK293 cells were significantly larger than 
digoxin (954 vs 8.2 fmol/cm2/min), which was expected considering that taurocholic acid 
is a high dose drug (1000-2000 mg/dose) while digoxin is a low dose drug (3-5 mg/dose).  
According to the above results, digoxin may be a weak substrate for ASBT. However, 
further inhibition studies using ketoconazole and verapamil on ASBT-HEK293 cell were 
required. 
 
4.4 Future direction  
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We will further investigate if Ostα-Ostβ transporter is a digoxin uptake transporter using 
co-transfected ASBT- Ostα-Ostβ−ΜDCK cell line, the only Ostα-Ostβ expressed cell 
line we can obtain.  
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4.5 Figures and tables 
 
 
Figure 1: Major bile acid transporters in the enterohepatic circulation.  
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Figure 2: Uptake of digoxin (A) and taurocholic acid (B) in wild type HEK293 and 
NTCP transfected HEK293 cells. NTCP-transfected and wildtype HEK293 cells were 
incubated with incubation media containing [3H] digoxin or [3H] taurocholic acid at 1 
µM. Each column represents the uptake of 3H] digoxin or [3H] taurocholic acid after 
30min incubation in fmol/cm2/min.  
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Figure 3: Uptake of digoxin in HEK293 cells expressing NTCP in the presence of 
ketoconazole (A) and verapamil (B). NTCP-transfected HEK293 cells were incubated 
with incubation media containing 1µM [3H] digoxin and various concentrations of 
ketoconazole and verapamil. Each column represents the uptake of 3H] digoxin 
taurocholic acid after 30min incubation in fmol/cm2/min.  
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A. 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
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Figure 4: Uptake of digoxin (A) and taurocholic acid (B) in wild type HEK293 and 
ASBT transfected HEK293 cells. ASBT-transfected and wildtype HEK293 cells were 
incubated with incubation media containing [3H] digoxin or [3H] taurocholic acid at 1 
µM. Each column represents the uptake of 3H] digoxin or [3H] taurocholic acid after 
30min incubation in fmol/cm2/min.  
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A. 
 
 
B. 
 
 
 
Figure 5: Chemical structure of taurocholic acid (A) and digoxin (B). They share 
structure of sterone-ring.  
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